

CURRICULUM VITAE

January 2021

Renée-Claude Mercier

Present Office Address

University of New Mexico
College of Pharmacy
2502 Marble NE
Albuquerque, NM 87131
PH (505) 272-0581/ FAX (505) 272-6749
Email: rmercier@salud.unm.edu

Place of Birth

Sherbrooke, Québec, Canada – Canadian Citizen
USA – US Citizen

Education and Training

D.E.C. in Sciences (1987-1989)

College of Sherbrooke
Sherbrooke, Québec. Canada

B.Sc. in Pharmacy (1989-1993)

Université Laval
School of Pharmacy
Ste-Foy, Québec. Canada

Doctorate in Pharmacy (Pharm.D.) (1993-1995)

Wayne State University
College of Pharmacy and Allied Health Sciences
Detroit, MI

Fellowship in Infectious Diseases (1995-1997)

Anti-Infective Research Laboratory
Detroit Receiving Hospital/University Health Center
Wayne State University
Detroit, MI
Preceptor: Michael J. Rybak, Pharm.D., FCCP

Board Certified Pharmacotherapy Specialists (BCPS)

Exam Passed October 7, 2000, Albuquerque, NM.
Recertified 2007, 2014.

Board Certified Pharmacotherapy Specialist with Added Qualifications in Infectious Diseases (AQ ID)

December 31, 2014 to December 31, 2021.

Licensed Pharmacist

Michigan (#5302029761)
New Mexico (#00006260), Pharmacist Clinician (#PC142)

Current and Previous Professional Experience

July 2019-present

Associate Medical Director

	UNM Truman Health Services Albuquerque, NM
July 2015-present	Professor (Tenured) of Pharmacy and Medicine University of New Mexico, College of Pharmacy Albuquerque, NM
July 2003-June 2015	Associate Professor (Tenured) of Pharmacy and Medicine University of New Mexico, College of Pharmacy Albuquerque, NM
October 2004-2006	PRN Staff Pharmacist University of New Mexico Hospitals Department of Pharmacy Albuquerque, NM
August 1997- June 2003	Assistant Professor of Pharmacy University of New Mexico, College of Pharmacy Albuquerque, NM
July 1995- June 1997	Research Associate, Fellow in Infectious Diseases Detroit Receiving Hospital/University Health Center Wayne State University Detroit, MI
July 1995- June 1997	Lecturer , Infectious Diseases Therapeutics Wayne State University Detroit, MI
Feb. – August 1993	Staff Pharmacist Pharmacie Chouinard & Vallee Disraeli, Québec. Canada
May 1992- Feb. 1993	Pharmacy Intern Pharmacie Chouinard & Vallee Disraeli, Québec. Canada

Professional Awards/Honors Received

2017	Dorothy Dillon Memorial Lecture Award
2017	University of New Mexico – College of Pharmacy, Teacher of the Year. PS-3
2016	Outstanding Clinical Practice in Infectious Diseases Pharmacotherapy Award from Society of Infectious Diseases Pharmacists
2016	The Bob Munk Memorial HIV Service Award
2015	Regent's Professor, University of New Mexico
2014	Fellow, American College of Clinical Pharmacy (FCCP)
2014	University of New Mexico – College of Pharmacy, Teacher of the Year. PS-3
2013	University of New Mexico – College of Pharmacy, Teacher of the Year. PS-3
2011	University of New Mexico – College of Pharmacy, Teacher of the Year. PS-3
2010	University of New Mexico – College of Pharmacy, Teacher of the Year. PS-3
2005	Regent's Lecturer, University of New Mexico

- 2005 Marshall, University of New Mexico College of Pharmacy Commencement.
2005 Invited to attend the Staphylococcal Diseases Gordon Research Conference
2001 Nominated for the Young Investigator Award from SIDP.
2001 Marshall, University of New Mexico College of Pharmacy Commencement.
1998-99 University of New Mexico – College of Pharmacy, Teacher of the Year.
1997 Rho Chi Scholastic Pharmacy Honor Society.
1993 Scholar of the Association des Pharmaciens du Québec.

Grants Awarded and Research Contracts

- 1. NMDOH Epidemiology and Laboratory Capacity** - Epidemiology and Laboratory Capacity, The Antimicrobial Stewardship Project. \$69,600. University of New Mexico – College of Pharmacy contract with DOH. Project Period 12/17/18-06/30/2019. Effort: 28%, UNM Principal Investigator
- 2. NMDOH Epidemiology and Laboratory Capacity** - Epidemiology and Laboratory Capacity, The Antimicrobial Stewardship Project. \$33,496.25. University of New Mexico – College of Pharmacy contract with DOH. Project Period 01/01/18-06/30/2018. Effort: 28%, UNM Principal Investigator
- 3. NMDOH Epidemiology and Laboratory Capacity** - Building and Strengthening Epidemiology. \$75,829. University of New Mexico – College of Pharmacy contract with DOH. Project Period 08/01/16-06/30/2017. Effort: 48%, UNM Principal Investigator
- 4. Shionogi Surveillance Study IHMA Inc.** (\$2,400). Sponsored by International Health Management Associates, Inc. University of New Mexico – College of Pharmacy. Project Period 08/01/16-09/30/2017 Effort: 0%, Principal Investigator.
- 5. Tricore Reference Laboratories.** Pharmacy Residency Affiliation Agreement. University of New Mexico, College of Pharmacy. Project Period 07/01/2016-06/30/2017. Effort: 5%; Principal Investigator
- 6. Durata Therapeutics.** \$15,000. Acute Bacterial Skin and Skin Practice Pattern Assessment Project-Site 102. University of New Mexico, College of Pharmacy. Project Period 08/04/2014-01/31/2015. Effort: 1%; Co-Principal Investigator
- 7. Tricore Reference Laboratories.** \$108,188. Pharmacy Residency Affiliation Agreement. University of New Mexico, College of Pharmacy. Project Period 07/01/2014-06/30/2016. Effort: 5%; Principal Investigator
- 8. University of New Mexico College of Pharmacy.** \$5,000. Biomarkers of Staphylococcus aureus infection in a high-risk population. Project Period 06/01/2013–01/31/2015. Co-Investigator
- 9. Cubist Pharmaceuticals.** \$1,500. MASS-ASOG DCAT Protocols. University of New Mexico, College of Pharmacy. Project Period 08/01/12-06/30/2013. Effort: 0%; Principal Investigator
- 10. Hartford Hospital.** \$1,800. Gram-negative organisms Collection Contract. University of New Mexico, College of Pharmacy. Project Period 10/01/13-03/31/2014. Effort: 0%; Principal Investigator
- 11. Hartford Hospital.** \$2,700. Staphylococcus aureus Collection Contract. University of New Mexico, College of Pharmacy. Project Period 10/01/12-03/31/2013. Effort: 0%; Principal Investigator
- 12. HAISS VA Palo Alto Contract.** \$171,637. Healthcare-Associate Infection & Influenza Surveillance System. University of New Mexico, College of Pharmacy. Project Period 10/01/12-09/30/2014. Effort: 60%; Principal Investigator
- 13. Cubist Clinical Trial.** \$33,320.00. A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization and Cost of Daptomycin vs. Vancomycin in

- the Treatment of Patients with Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-Resistant *Staphylococcus aureus* (MRSA). Project Period 11/1/2011 – 10/1/2012. Effort: 1%; Principal Investigator.
14. **Health Sciences Center Research Allocation Committee Grant.** \$10,000. Effect of continuous infusion of piperacillin/tazobactam on vancomycin MRSA activity. Project Period: 05/01/10-04/30/11. Effort: Not allowed; Principal Investigator
 15. **ASHP Foundation, Pharmacy Resident Practice-Based Research Grant.** \$5,000. Impact of a pharmacy adherence clinic on HIV medication taking self-efficacy: a single-group, pretest-posttest study. University of New Mexico, College of Pharmacy. Project Period: 1/1/2012-12/31/12 Effort: Not allowed; Faculty Mentor
 16. **HAISS VA Palo Alto Contract.** \$77,270. Healthcare-Associate Infection & Influenza Surveillance System. University of New Mexico, College of Pharmacy. Project Period 10/01/11-07/31/12 Effort: 60%; Principal Investigator
 17. **Health Sciences Center Research Allocation Committee Grant.** \$10,000. Optimization of hepatitis B vaccine in HIV-infected patients. University of New Mexico-College of Pharmacy. Project Period: 05/01/10-04/30/11. Co-Investigator.
 18. **Health Sciences Center Research Allocation Committee Grant.** \$10,000. Trimethoprim and sulfamethoxazole transmembrane clearance during CRRT. University of New Mexico-College of Pharmacy. Project Period: 05/01/10-04/30/11. Co-Investigator.
 19. **Astellas Pharmaceuticals.** \$45,911. Relationship of In Vitro MRSA Strain Characteristics to Telavancin Susceptibility: A Multicenter Evaluation. University of New Mexico, College of Pharmacy. Project Period 2010-2011. Principal-Investigator.
 20. **Pfizer Aspire Grant.** \$100,000. Linezolid-mediated potentiation of host defense efficacy against MRSA and MSSA. University of New Mexico, College of Pharmacy. Project Period 2009-2010. Co-Investigator/Mentor.
 21. **HAISS VA Palo Alto Contract.** \$237,915. Healthcare-Associate Infection & Influenza Surveillance System. University of New Mexico, College of Pharmacy. Project Period 2008-2011. Principal-Investigator.
 22. **Cubist Pharmaceuticals.** Investigator Initiated Grant. \$38,897. Assessment of susceptibility testing methods for predicting outcomes of methicillin-resistant *Staphylococcus aureus* bloodstream infections from two tertiary care institutions. University of New Mexico, College of Pharmacy. Project Period 2009-2010. Principal-Investigator.
 23. **American Heart Association.** \$85,000. Role and regulation of D-alanylation of Teichoic acids in *Staphylococcus aureus*. PI: Koprivnjak, Tomaz Ph.D., University of Iowa, Postdoctoral Fellowship. Project Period 7/1/2007-6/30/2009. Collaborative Investigator.
 24. **Astellas Pharma, Inc.** Research Grant, pMS-06-001. \$30,492. Pharmacodynamic evaluation of micafungin, liposomal amphotericin B, and flucytosine in an in vitro fibrin clot model of *Candida albicans* infective endocarditis. University of New Mexico, College of Pharmacy. Project Period 2006-2007. Co-Investigator.
 25. **Society of Infectious Diseases Pharmacists.** \$20,000. Pharmacodynamic evaluation of antifungals in an in vitro model of *Candida albicans* infective endocarditis. University of New Mexico, College of Pharmacy. Project Period 2005-2006. Co-Investigator.
 26. **Cubist Pharmaceuticals, Inc.** Independent Research Grant. \$26,069. Investigator Initiated. Characterization of daptomycin pharmacokinetics and glomerular filtration rate in morbidly obese patients. University of New Mexico, College of Pharmacy. Project Period: 2005-2006. Co-Investigator.

27. **Pfizer, Inc.** \$10,062. Investigator Initiated. Retrospective analysis of vancomycin-induced neutropenia in patients with serious gram-positive infection. University of New Mexico, College of Pharmacy. Project Period: 2004-2005. Co - Investigator.
28. **Ortho-McNeil.** \$7,000. Funding provided to implement a Statewide Residents and Fellows Journal Club Series. Restricted Grant from Ortho-McNeil to Renee-Claude Mercier and the University of New Mexico. Project Period: July 2001-2002.
29. **American Society for Microbiology (ASM) Undergraduate Research Fellowship.** \$4,000. Staphylococcus aureus competitive advantage in infective endocarditis. Undergraduate student: Robert Dietz. University of New Mexico-College of Pharmacy. Project Period: 06/01/2001-5/31/02. Faculty Mentor.
30. **Wyeth-Ayerst Research.** Investigator initiated research. \$ 38,415. Pharmacodynamic Evaluation of GAR-936 against Staphylococcus aureus and Enterococcus faecalis. University of New Mexico-College of Pharmacy. Project Period: 06/01/2001-05/31/03. Principal Investigator.
31. **General Clinical Research Center (NIH MO1-RR00997).** All Research Cost Funded through GCRC program. Association between protease inhibitors and thromboembolic complications in HIV infected patients (HRRC #99-331). University of New Mexico-College of Pharmacy and School of Medicine. Project Period: 01/01/2000-12/31/2000. Principal Investigator.
32. **Society of Infectious Diseases Pharmacists/Pfizer Research Award.** \$19,540. Thrombin-induced platelet microbicidal protein alone and in combination with vancomycin and nafcillin in an in vitro endocarditis model of infection. University of New Mexico-College of Pharmacy. Project Period: 10/1/99-9/30/2000. Principal Investigator.
33. **Society of Infectious Diseases Pharmacists/Pfizer Research Award.** \$20,000. Interactions of platelets and vancomycin-resistant Enterococcus faecium in an in vitro model of infective endocarditis. University of New Mexico-College of Pharmacy. Project Period: 10/1/98-9/30/99. Principal Investigator.
34. **Health Sciences Center Research Allocation Committee Grant.** \$5,000. Mechanisms by which platelets and platelet microbicidal proteins mediate antibacterial effects in an in vitro endocarditis model of infection. University of New Mexico-College of Pharmacy. Project Period: 01/01/98-12/31/98. Principal Investigator.
35. **Society of Infectious Diseases Pharmacists/Pfizer Research Award.** \$30,000. In vitro interactions of platelets and Staphylococcus aureus strain pairs with differing intrinsic susceptibility to platelet microbicidal proteins. Wayne State University-College of Pharmacy. Project Period: 1996-1997. Principal Investigator.
36. **Eli Lilly & Company Research Grant.** \$30,000. Pharmacodynamic Evaluation of LY333328 Compared to Vancomycin. Wayne State University-College of Pharmacy. Project Period: 1995-1996. Co-Principal Investigator.

NIH Grants Submitted.

1. **National Institute of Health.** PA-13-302 \$2,263,266.00. Modulating the MRSA Resistome to Enhance Antibiotic Efficacy. PI: Michael Yeaman PhD., UCLA. **1R01-030463 01.** Submitted 10/03/2014. **Co-Investigator.**
2. **National Institute of Health.** \$1,441,536. Salicylate Mitigation of Antibiotic Resistance in MRSA. PI: Michael Yeaman PhD., UCLA. **1R01-AI079509-01.** Submitted 10/18/2007. Priority Score: 237. Not Funded. **Co-Investigator.**
3. **National Institute of Health.** PA-04-119 \$1,793,337 (UNM \$302,142). Anti-Staphylococcal Mechanisms of Platelets. PI: Michael Yeaman PhD., UCLA. **1R01 AI073909-01.** Submitted June 1, 2006. Priority Score: 259. Not Funded. **Co-Investigator.**

Grant Expenditures Active COP/NON-COP Awards with Salary Support (2020) = Total Salary Support %

- 2020 Project ECHO.
South Central AIDS Education and Training Center Program Health Resources and Services Administration
Non-COP Active Funding: \$6,779,905.00. Dates Funded: July 1, 2020 - June 30, 2021
% Salary support: 3.5 %
- 2020 SC AETC Support of HRSA COVID-19 Response Grant
Non-COP Active Funding: \$400,000.00. Dates Funded: April 1, 2020 – March 31, 2021.
% Salary support: 0.75 %
- 2020 Truman Health Services.
Ryan White HIV/AIDS Program Part D Coordinated HIV Services and Access to Research for Women, Infants, Children, and Youth (WICY) Health Resources and Services Administration
Non-COP Active Funding: \$2,080,963.00. Dates Funded: August 1, 2017 - July 31, 2021
Ryan White Part C Outpatient EIS Program Health Resources and Services Administration
Non-COP Active Funding: \$2,155,683.00. Dates Funded: April 1, 2018 - March 31, 2021
% Salary support %40.67

Other sources (UNMMG, IM Infectious disease, contract pharmacy, BH): **16.8%**

UNM College of Pharmacy Salary Support for 2020: 38.25%

Original Research Publications in Peer-Reviewed Journals

1. Custodio MM, Sanchez D, Anderson B, Ryan KL, Walraven C, **Mercier RC**. Emergence of resistance in *Klebsiella aerogenes* to piperacillin-tazobactam and ceftriaxone. *Antimicrob Agents Chemother*. 2020 Nov 2;AAC.01038-20. doi: 10.1128/AAC.01038-20. Epub ahead of print. PMID: 33139285.
2. Ryan KL, Jakeman B, Conklin J, Pineda LJ, Deming P, **Mercier RC**. Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home. *Am J Health Syst Pharm*. 2019 May 17;76(11):821-828. doi: 10.1093/ajhp/zxz059. PMID: 31053839.
3. Dilworth TJ; Casapao AM; Ibrahim OM; Jacobs DM; Bowers DR; Beyda ND; **Mercier RC**. Adjuvant B-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Does B-Lactam Class Matter? *Antimicrob Agents Chemother*. 2019;63(3) DOI: 10.1128/AAC.02211-18.
4. Dilworth TJ, Sanchez D, Anderson B, DeAngelis H, **Mercier RC**. Exploring the Role of Piperacillin and Tazobactam in Combination with Vancomycin against Methicillin-Resistant *Staphylococcus aureus*. *Chemotherapy*. 2019;64(5-6):233-237. doi: 10.1159/000507241. Epub 2020 May 12. PMID: 32396913.
5. Dodd M, Adolphe A, Parada, A, Brett M, Culbreath K, **Mercier RC**. Clinical Impact of a Rapid Streptococcal Antigen Test on Antibiotic Use in Adult Patients. *Diagn Microbiol Infect Dis*. 2018 Aug;91(4):339-344. doi: 10.1016/j.diagmicrobio.2018.03.018. Epub 2018 Apr 7. PMID:29731388
6. Dilworth TJ, Klein PW, **Mercier RC**, Borrego ME, Jakeman B, Pinkerton SD. Clinical and Economic Effects of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV. *J Manag Care Spec Pharm*. 2018;24 (2):165-172.
7. Vazquez Guillamet MC, Vazquez R, Deaton B, Shroba J, Vazquez L, **Mercier RC**. Host - pathogen - treatment triad: host factors matter most in MRSA bacteremia

- outcomes. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2). pii: e01902-17. doi: 10.1128/AAC.01902-17. Print 2018 Feb. PMID: 29203479.
8. Dionne B, Brett M, Culbreath K, **Mercier RC**. Potential Ceiling Effect of Healthcare Worker Influenza Vaccination on the Incidence of Nosocomial Influenza Infection. *Infect Control Hosp Epidemiol*. 2016 Apr 21:1-5. [Epub ahead of print]. PMID: 27098758
 9. Marshik PL, Kharat AA, Jakeman B, Borrego ME, Dodd MA, Bachyrycz A, Anderson JR, Bond R, Deming P, **Mercier RC**, Nawarskas JJ, Ray G, Salazar K. Complementary and Alternative Medicine and Therapy Use in a Diverse New Mexican Population. *J Altern Complement Med*. 2016 Jan;22(1):45-51 doi: 10.1089/acm.2014.0378. Epub 2015 Nov 5. PMID: 26539688.
 10. Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska P, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, **Mercier RC**, Garcia-Diaz J, Brenneman SK, Ng, Lodise T. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. *BMC Infect Dis*. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9. PMID: 26547411
 11. Pineda LJ, **Mercier RC**, Dilworth T, Iandiorio M, Rankin S, Jakeman B. Evaluating community pharmacists' HIV testing knowledge: A cross-sectional survey. *J Am Pharm Assoc*. 2015;55(4):424-8. doi: 10.1331/JAPhA.2015.14139. PMID: 26161484.
 12. Ross JL, Rankin S, Marshik P, **Mercier RC**, Brett M, Walraven CJ. Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin. *Antibiotics (Basel)*. 2015 Jul 24;4(3):309-20. doi: 10.3390/antibiotics4030309.
 13. Yardman-Frank JM, **Mercier RC**, Wong CS, Vilay AM. Iohexol Transmembrane Clearance During Modeled Continuous Renal Replacement Therapy. *Blood Purif* 2015;39 (1-3):188-92.
 14. Kesner JM, Yardman JM, **Mercier RC**, Wong CS, Walker SE, Argyres DP, Vilay AM. Trimethoprim and Sulfamethoxazole Transmembrane Clearance during Modeled Continuous Renal Replacement Therapy. *Blood Purif* 2014;38:195-202. doi: 10.1159/000368884.
 15. Dilworth TJ, Ibrahim O, **Mercier RC**. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with *Pneumocystis jirovecii* pneumonia. *J Manag Care Pharm* 2014 Dec;20(12):1246-54. PMID:25443518
 16. Ibrahim OM, Dilworth TJ, **Mercier RC**. Reply to "Probability of Eradication Using Vancomycin Alone or in Combination for Methicillin-Resistant *Staphylococcus aureus* Bacteremia". *Antimicrob Agents Chemother*. 2014 Dec;58(12):7618-9. doi: 10.1128/AAC.03824-14. PMID:25392537
 17. Hermsen ED, McDanel PM, Eiland E, Destache CJ, Lusardi KT, Estrada SJ, **Mercier RC**, DePestel DD, Lamp KC, Anderson E, Chung T, McKinnon P. Breaking Down the Barriers: Challenges With Development and Implementation of an Industry-Sponsored Antimicrobial Stewardship Data Collection and Analysis Tool. *Clin Infect Dis*. 2014 Oct 15;59 Suppl 3:S170-84. doi: 10.1093/cid/ciu539. PMID: 25261545
 18. DePestel DD, Eiland EH, Lusardi K, Destache C, **Mercier RC**, McDanel PM, Lamp KC, Chung T, Hermsen ED. Assessing Appropriateness of Antimicrobial Therapy: In the Eye of the Interpreter. *Clin Infect Dis*. 2014 Oct 15;59 Suppl 3:S154-61. doi: 10.1093/cid/ciu548. PMID: 25261542
 19. Dilworth TJ, Leonard SN, Vilay AM, **Mercier RC**. Vancomycin and Piperacillin-Tazobactam Against Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Intermediate *Staphylococcus aureus* in an In Vitro Pharmacokinetic/Pharmacodynamic

- Model. Clin Ther. 2014 Oct 1;36(10):1334-44. doi: 10.1016/j.clinthera.2014.06.027. Epub 2014 Jul 25.PMID:25066667
20. Dilworth TJ, Sliwinski J, Ryan K, Dodd M, **Mercier RC**. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant *Staphylococcus aureus* isolates and vancomycin-intermediate *Staphylococcus aureus* isolates in vitro. Antimicrob Agents Chemother. 2014;58(2):1028-33. doi: 10.1128/AAC.01888-13. Epub 2013 Nov 25.PMID:24277036
 21. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, **Mercier RC**. B-lactams Enhance Vancomycin Activity against Methicillin-Resistant *Staphylococcus aureus* Bacteremia Compared to Vancomycin Alone. Antimicrob Agents Chemother. 2014;58(1):102-9. doi: 10.1128/AAC.01204-13. Epub 2013 Oct 21.PMID:24145519
 22. Vilay AM, WongCS, Schrader RM, **Mercier RC**, Seifert SA. Indicators for serious kidney complications associated with toxic exposures: an analysis of the National Poison Data System. Clin Toxicol (Phila). 2013 Feb;51(2):96-105. doi: 10.3109/15563650.2012.762456. Epub 2013 Jan 19.PMID:23331216
 23. Schirmer PL, **Mercier RC**, Ryono RA, Nguyen N, Lucero CA, Oda G, Holodniy M. Comparative Assessment of Antimicrobial Usage Measures in the Department of Veterans Affairs. Infect Control Hosp Epidemiol. 2012 Apr;33(4):409-11. doi: 10.1086/664759.PMID:22418639
 24. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, **Mercier RC**. Site of Infection Rather Than Vancomycin Minimum Inhibitory Concentration (MIC) Predicts Vancomycin Treatment Failure in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia. J Antimicrob Chemother. 2011 Oct;66(10):2386-92. doi: 10.1093/jac/dkr301. Epub 2011 Jul 20.PMID:21775337
 25. Pai MP, Samples ML, **Mercier RC**, Spilde MN. Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother. 2008 Jul;52(7):2367-76. doi: 10.1128/AAC.01557-07. Epub 2008 Apr 21.PMID:18426896
 26. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, **Mercier RC**. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7. Epub 2007 Jun 4.PMID:17548489
 27. Barton Pai A, Pai MP, Depczynski J, McQuade CR, **Mercier RC**. Non-transferrin-bound iron is associated with enhanced *Staphylococcus aureus* growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol. 2006;26(3):304-9. Epub 2006 Jun 29.PMID:16809897
 28. Pai MP, **Mercier RC**, Allen SE. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Ann Pharmacother. 2006 Mar;40(3):553-8. Epub 2006 Feb 28.PMID:16507618
 29. Pai MP, **Mercier RC**, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann Pharmacother. 2006 Feb;40(2):224-8. Epub 2006 Jan 24.PMID:16434560
 30. Hawkins T, Geist C, Young B, Giblin A, **Mercier RC**, Thornton K, Haubrich R. Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients. HIV Clin Trials. 2005 Jul-Aug;6(4):187-96.PMID:16214735
 31. **Mercier RC**, Dietz RM, Mazzola J, Bayer AS, Yeaman MR. Beneficial Influence of Platelets on Antibiotic Efficacy in an In Vitro Model of *Staphylococcus aureus*-Induced Endocarditis. Antimicrob Agents Chemother. 2004 Jul;48(7):2551-7.PMID:15215108

32. Graham AC, **Mercier RC**, Achusim LE, Pai MP. Extended-Interval Aminoglycoside Dosing for Treatment of Enterococcal and Staphylococcal Osteomyelitis. *Ann Pharmacother*. 2004 Jun;38(6):936-41. Epub 2004 Apr 14. PMID:15084688
33. White RL, Bonapace CR, Friedrich LV, Rybak MJ, Cappelletty DM, **Mercier RC**, Houlihan HH, Aeschlimann JR, Bosso JA. Assessment of Differences in Antimicrobial Effect Determined with Two In Vitro Pharmacodynamic Models: Impact of Surface Area to Volume Ratio. *Pharmacotherapy*. 2003 May;23(5):603-8. PMID:12741434
34. **Mercier RC**, Kennedy C, Meadows C. Antimicrobial Activity of Tigecycline (GAR-936) against *Enterococcus faecium* and *Staphylococcus aureus* Used Alone and in Combination. *Pharmacotherapy*. 2002 Dec;22(12):1517-23. PMID:12495161
35. **Mercier RC**, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavacin (LY333328), against *Staphylococcus aureus* and *Enterococcus faecium*. *J Antimicrob Chemother*. 2002 Jul;50(1):19-24. PMID:12096002
36. Klepser ME, Lewis RE, Ernst EJ, Petzold CR, Bailey EM, Burgess DS, Carver PL, Lacy MK, **Mercier RC**, Nicolau DP, Zhanel GG, Pfaller MA. Multi-center evaluation of antifungal time-kill methods. *J Infect Dis Pharmacother*. 2001;5:29-41.
37. **Mercier RC**, Rybak MJ, Bayer AS, Yeaman MR. Influence of platelets and platelet microbicidal protein susceptibility on the fate of *Staphylococcus aureus* in an in vitro model of infective endocarditis. *Infect Immun*. 2000 Aug;68(8):4699-705. PMID:10899875
38. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, **Mercier RC**, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother*. 1998 Apr;42(4):981-3. PMID:9559828
39. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, **Mercier RC**, Rybak MJ. Efficacy of trovafloxacin against experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother*. 1998 Feb;42(2):254-6. PMID:9527768
40. **Mercier RC**, Penzak SR, Rybak MJ. In vitro activity of investigational antibiotics alone and in combinations against two strains of vancomycin-resistant *Enterococcus faecium* (VREF). *Antimicrob Agents Chemother*. 1997 Nov;41(11):2573-5. PMID:9371372
41. Houlihan HH, **Mercier RC**, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant *Staphylococcus aureus*-Infected Fibrin-Platelet Clots in an in vitro infection model. *Antimicrob Agents Chemother*. 1997 Nov;41(11):2497-501. PMID:9371356
42. Rybak MJ, Houlihan HH, **Mercier RC**, Kaatz GW. Pharmacodynamics (PD) of RP 59500 (RP) (Quinupristin/Dalfopristin) administered by intermittent versus continuous infusion against *Staphylococcus aureus* infected fibrin-platelet clots in an in vitro infection model. *Antimicrob Agents Chemother*. 1997 Jun;41(6):1359-63. PMID:9174199
43. **Mercier RC**, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation and in vitro activity of a new glycopeptide, LY333328 against *Staphylococcus aureus* and *Enterococcus faecium*. *Antimicrob Agents Chemother*. 1997 Jun;41(6):1307-12. PMID:9174189
44. Cappelletty DM, **Mercier RC**, Rybak MJ. Evaluation of the bactericidal and synergistic activity of a glycylicycline, CL 331,002 vs. Vancomycin, ofloxacin, minocycline, tetracycline against methicillin-resistant *Staphylococcus aureus* and vancomycin resistant *Enterococcus faecium*. *J Infect Dis Pharmacother* 1996;2:57-64.

Review article in Peer-Reviewed Journals

1. Walraven CJ, **RC Mercier**, and SA Lee. 2011 Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients. *Curr Fungal Infect Rep*. Published online 11 Feb. 2011. 2011;5(2):67-74.

2. **Mercier RC**, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. *Expert Rev Anti Infect Ther.* 2005 Jun;3(3):325-32. Review.PMID:15954849
3. Dominguez KD, **Mercier RC**. Treatment of RSV pneumonia in adults – Evidence of ribavirin effectiveness? *Ann Pharmacother.* 1999 Jun;33(6):739-41. PMID:10410189

Book Chapters

1. Deming P, **Mercier RC**. (2020). Intra-abdominal Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 11th ed., Ch.131 , PP. 345-6. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 11th ed., McGraw-Hill, New York, NY.
2. **Mercier RC**, Deming P. (2020). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 11th ed., Ch.127, PP. 335-7. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 11th ed., McGraw-Hill, New York, NY.
3. **Mercier RC**, Mertz GJ. (2018). Aciclovir and Valaciclovir. In: Grayson, L. (ed), *Kucer's The Use of Antibiotics.* 7th ed. Ch. 213, PP. 3449-3492, CRC Press, Taylor & Francis Group LLC, Boca Raton, FL.
4. Deming P, **Mercier RC**. (2017). Intra-abdominal Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 10th ed., Ch.131 , PP. 340-342. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 10th ed., McGraw-Hill, New York, NY.
5. **Mercier RC**, Deming P. (2017). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 10th ed., Ch.127, PP. 330-332. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 10th ed., McGraw-Hill, New York, NY.
6. **Mercier RC**, Walraven CJ. (2017). Technologic Support for Antimicrobial Stewardship. In Laplante K (ed), *Antibiotic Stewardship: Principles & Practice.* 1st ed., Ch 27. CABI Wallingford, Oxfordshire, UK
7. **Mercier RC**, Jakeman B, Pineda L. (2016). Antiviral Agents. In Rotschafer, J.C., Andes D.R., and Rodvold K.A. (eds), *Antibiotic Pharmacodynamics, Methods in Pharmacology and Toxicology.* 1st ed., Ch 18. Springer Science+Business Media, New York, NY.
8. **Mercier RC**, Deming P. (2014). Intra-abdominal Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 9th ed., Ch. 131, PP. 344-346. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 9th ed., McGraw-Hill, New York, NY.
9. **Mercier RC**, Deming P. (2014). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 9th ed., Ch.127, PP. 334-6. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 9th ed., McGraw-Hill, New York, NY.
10. **Mercier RC**, Deming P. (2011). Intra-abdominal Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 8th ed., Ch. 130, PP. 335-7. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 8th ed., McGraw-Hill, New York, NY.
11. **Mercier RC**, Deming P. (2011). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 8th ed., Ch. 126, PP. 325-7. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 8th ed., McGraw-Hill, New York, NY.
12. GJ Mertz, **Mercier RC**. (2010). Valaciclovir. In: Grayson, L. (ed), *Kucer's The Use of Antibiotics.* 6th ed. Ch. 210, PP. 2361-9, Hodder & Stoughton Ltd, London, England.

13. **Mercier RC**, Mertz GJ. (2010). Aciclovir. In: Grayson, L. (ed), Kucer's The Use of Antibiotics. 6th ed. Ch. 209, PP. 2333-60, Hodder & Stoughton Ltd, London, England.
14. **Mercier RC**. (2010). Aminoglycosides. In Smith, K.M., D.M. Riche, and N.N. Henyan (eds). Clinical Drug Data. 11th ed., Ch. 6, PP. 75-82, McGraw-Hill, New York, NY.
15. **Mercier RC**, Graham AC. (2008). Intra-abdominal Infection. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 7th ed., Ch. 122, PP 297-299. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 7th ed., PP. McGraw-Hill, New York, NY.
16. Graham AC, **Mercier RC**. (2008). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 7th ed., Ch. 118, PP. 288-290. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 7th ed., McGraw-Hill, New York, NY.
17. **Mercier RC**, Graham AC. (2005). Intra-abdominal Infections. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 6th ed., Ch. 120, PP. 316-8. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 6th ed., PP. McGraw-Hill, New York, NY.
18. **Mercier RC**, Graham AC. (2005). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 6th ed., Ch. 116, PP.307-9. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 6th ed., McGraw-Hill, New York, NY.
19. Pai MP, **Mercier RC**, Raebel MA. (2005). Viral hepatitis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A Pathophysiologic Approach 6th ed., PP.737-759. McGraw-Hill, New York, NY.
20. **Mercier RC**. (2002). Intra-abdominal Infections. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 5th ed., Ch. 121, PP. 311-13. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 5th ed., PP. 1191-1196. Appleton & Lange, Stamford, CT.
21. **Mercier RC**. (2002). Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 5th ed., Ch. 117, PP. 302-304. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 5th ed., PP. 1157-1164. Appleton & Lange, Stamford, CT.
22. **Mercier RC**. (2002). Miscellaneous Antibiotics. In Anderson, P.O., J.E. Knoben, and W.G. Troutman (eds.) Handbook of Clinical Drug Data. 10th ed. PP. 181-194, Appleton & Lange, Stamford, CT.
23. **Mercier RC**. (2002). Quinolones. In Anderson, P.O., J.E. Knoben, and W.G. Troutman (eds.) Handbook of Clinical Drug Data. 10th ed. PP. 166-172, Appleton & Lange, Stamford, CT.
24. **Mercier RC**. (2002). Beta-lactams. In Anderson, P.O., J.E. Knoben, and W.G. Troutman (eds.) Handbook of Clinical Drug Data. 10th ed. PP. 126-158, Appleton & Lange, Stamford, CT.
25. **Mercier RC**. (2002). Aminoglycosides. In Anderson, P.O., J.E. Knoben, and W.G. Troutman (eds.), Handbook of Clinical Drug Data. 10th ed. PP. 55-61, Appleton & Lange, Stamford, CT.
26. **Mercier RC**. (2001). Infective Endocarditis. In: Mueller, B.A., et al. (eds.), Pharmacotherapy Self-Assessment Program, Book 4, Infectious Diseases I, II, 4th ed., American College of Clinical Pharmacy, Kansas City, MO. PP. 259-283
27. **Mercier RC**. (2000). Intra-abdominal Infections. In Schwinghammer, T.L. (ed.), Pharmacotherapy Casebook, a patient-focused approach. 2nd ed., Ch. 103, PP. 257-259. And Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach. 2nd ed., PP. 337-338. Appleton & Lange, Stamford, CT.

28. **Mercier RC.** (2000) Diabetic Foot Infection. In Schwinghammer, T.L. (ed.), *Pharmacotherapy Casebook, a patient-focused approach.* 2nd ed., Ch. 99, PP. 248-250. And *Instructor's Guide to accompany Pharmacotherapy Casebook, a patient-focused approach.* 2nd ed., PP. 324-327. Appleton & Lange, Stamford, CT.

Scientific Papers Presented Nationally and Internationally

1. DeAngelis H, **Mercier RC.** Examining the combination of cefixime and amoxicillin/clavulanate against extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* isolates. Poster Presentation at the American College of Clinical Pharmacy October 29, 2019. New York, NY.
2. Sanchez D, Borrego M, Newsome C, **Mercier RC,** Conklin J. Barriers to Acquiring Pre-Exposure Prophylaxis (PrEP), Risk Factors for HIV, and Health Determinants in Adult Transgender Individuals. Poster presentation at ID Week 2019. October 4, 2019. Washington, DC. Poster 1279.
3. Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, **Mercier RC.** Adjuvant β -lactam therapy combined with vancomycin for methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia: Does β -lactam class matter? Poster presentation at ID Week 2018; Oct 5, 2018. San Francisco, CA. Poster 1066.
4. Custodio M, Anderson B, Sanchez D, Ryan K, Walraven C, **Mercier RC.** Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in *Klebsiella aerogenes*. Poster presentation at ID Week 2018; Oct 5, 2018. San Francisco, CA. Poster 1414.
5. Ryan K, Lewis J, Sanchez D, Anderson B, **Mercier RC.** The Next Step in PrEP: Evaluating Outcomes of a Pharmacist-Run HIV Pre-Exposure Prophylaxis (PrEP) Clinic. Poster presentation at ID Week 2018; Oct 5, 2018. San Francisco, CA. Poster 1293.
6. Kesner J, Lewis J, Bustamante A, **Mercier RC.** From Cefazolin In Vitro Susceptibility to Clinical Use of Cephalexin: Could we be wrong? Poster presentation at the ASM Microbe meeting; June 1-5, 2017; New Orleans, LA. Poster 420.
7. Dilworth TJ, Klein PW (presenting author), **Mercier RC,** Borrego ME, Jakeman B, Pinkerton SD. Clinical Impact and Cost-Effectiveness of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV. Poster presentation at the United States Conference on AIDS (Poster Presentation #718). Washington, DC. September 10-13, 2015.
8. Vazquez-Guillamet MC, Shroba JJ, Deaton D, Vazquez R, Bernauer ML, **Mercier RC.** Trajectory and Long-Term Outcomes in Patients with MRSA Bacteremia. Platform presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Session Number 121, CE 0391-9999-15-112-L04-P.
9. Bernauer ML, Lewis JM, Shroba JJ, **Mercier RC.** Application of Supervised Learning Algorithms for Rapid Identification of MRSA PFGE Strain Types. Poster presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Poster C-1045.
10. Shroba JJ, Dilworth TJ, Bernauer ML, **Mercier RC.** Clinical and Microbiological Characterization of Recurrent Invasive Methicillin Resistant *Staphylococcus aureus* (MRSA) Infection. Poster presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Poster K-812.
11. Dionne B, Brett M, Culbreath K, **Mercier RC.** Limited effect of healthcare worker influenza vaccination rates on the incidence of nosocomial influenza infections. Poster

- presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Poster I-296.
12. Dodd MR, Culbreath K, Brett M, Adolphe A, **Mercier RC**. Clinical Impact of a Rapid Streptococcal Antigen Test on Antibiotic Use. Poster presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Poster S-895.
 13. Ryan KL, Shroba JJ, Sarangam D, Walraven C, **Mercier RC**. Swimming in Urine, Drowning in Cost: An Evaluation of Urinalysis Outcomes in the Emergency Department. Platform presented at: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy; September 18-21, 2015; San Diego, CA. Session Number 123, CE 0391-9999-15-114-L04-P.
 14. Schirmer P, **Mercier RC**, Lucero-Obusan C, Oda G, Holodniy M. Pertussis Surveillance in Veterans Affairs Medical Centers in Western United States – 2010-2014. Presented at the International Society for Disease Surveillance, December 2014.
 15. Pineda LJ, Johnson B, Iandiorio M, Rankin S, Dilworth TJ, Weese J, **Mercier RC**. Evaluating Human Immunodeficiency Virus (HIV) Screening and OraQuick In-Home HIV Test Knowledge: A Survey of New Mexico Pharmacists. Presented at the American College of Clinical Pharmacy 2013 Annual Meeting (Abstract Number 102), Albuquerque, NM. October 15, 2013.
 16. Dilworth TJ, Pineda LJ, Sliwinski J, **Mercier RC**. Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis: A 10 Year Retrospective Analysis from a Tertiary Care, Academic Medical Center. Presented at the American College of Clinical Pharmacy 2013 Annual Meeting (Abstract Number 121E), Albuquerque, NM. October 15, 2013.
 17. Dilworth TJ, Pineda LJ, Sliwinski J, **Mercier RC**. Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE): A 10 Year Retrospective Analysis from a Tertiary Care, Academic Medical Center. Presented at the 53rd Interscience Conference of Antimicrobial Agents and Chemotherapy (Control Number K-1274), Denver, CO. September 12, 2013.
 18. Dodd MR, Acosta JM, **Mercier RC**. The Effects of Linezolid on Methicillin-Resistant *Staphylococcus aureus* (MRSA) Panton-Valentine Leukocidin (PVL) Production Utilizing an Enzyme Liked Immuno Sorbent Assay. Presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Control Number 2487), Denver, CO. September 10, 2013.
 19. Dilworth TJ, Leonard S, Vilay AM, **Mercier RC**. Vancomycin (VAN) and Piperacillin-Tazobactam (PT) against Methicillin-Resistant *Staphylococcus aureus* (MRSA) and VAN-Intermediate *Staphylococcus aureus* (VISA) in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model. Presented at the 53rd Interscience Conference of Antimicrobial Agents and Chemotherapy (Control Number 2362), Denver, CO. September 10, 2013.
 20. Dilworth T, **Mercier R**. Impact of a national intravenous trimethoprim/sulphamethoxazole (IV TMP/SMX) shortage on treatment outcomes in HIV-positive patients with *Pneumocystis jirovecii* pneumonia (PJP): a retrospective, quasi-experimental analysis. (Abstract #3600). Presentation at the 23rd European Congress of Clinical Microbiology and Infectious Diseases. April 27, 2013. Berlin, Germany.
 21. Schirmer P, **Mercier RC**, Ryono R, Lucero C, Oda G, Holodniy M. Initial Testing of a VA Enterprise Solution for Institutional Antibiograms. (Infectious Diseases Society of America, IDWeek, 2012).
 22. Oda G, **Mercier R**, Schirmer P, Grishkan A, Cook J, Holodniy M. Incorporation of Antimicrobial Orders in an Automated Surveillance Algorithm for Detection of Surgical Site Infections. (Infectious Diseases Society of America, IDWeek, 2012).

23. Ryan K, Jett S, **Mercier RC**. Thickened Cell wall as a Mechanism for Increased Telavancin Minimum Inhibitory Concentration (MIC) in Methicillin-Resistant *Staphylococcus aureus* (MRSA). Presentation at the 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (Abstr. C1-1742), September 11, 2012. San Francisco, CA.
24. Dilworth TJ, Sliwinski J, Ryan K, Dodd M, **Mercier RC**. Beta-lactams Enhance Vancomycin Killing Activity against Clinical Methicillin-Resistant *Staphylococcus aureus* in vitro. Presentation at the 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (Abstr. E-1472), September 11, 2012. San Francisco, CA.
25. Borrego ME, Marshik P, Kharat A, Bachyrycz A, Dodd M, Anderson J, Bond R, Deming P, Goddard N, Johnson B, **Mercier R**, Nawarskas J, Ray G, Salazar, K. Attitudes, Experience and Use Regarding Complementary and Alternative Medicines and Therapies (CAMT) in People Living in New Mexico. Accepted for presentation at the Annual Meeting of the American Pharmacists Association, New Orleans, LA, March 9-12, 2012. [Abstract #175]
26. Sliwinski J, Precit M, **Mercier RC**. Relationship of In Vitro MRSA Strain Characteristics to Telavancin Susceptibility: A Multicenter Evaluation. 51st Annual meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011. [Abstract #E-1333]
27. **Mercier RC**, Montoya MT, Boyd NK, Wang H, Bayer AS, Yeaman MR. Linezolid (LZD) Suppresses Virulence Factor Expression and Potentiates Host Defense Efficacy Against MRSA Clonotype Strain USA300. 51st Annual meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011. [Abstract #B-049]
28. Schirmer P, **Mercier RC**, Oda G, Nguyen N, Ryono R, Holodniy M. Drug Consumption Determination Comparing Bar Code Medication Administration (BCMA) Data to Standard Methods within the Veterans Affairs (VA) Health Care System (Making a Difference in Infectious Diseases Conference, 2011).
29. Schirmer PL, **Mercier RC**, Oda G, Lucero C, Bau B, Lewis, Canody C, Holodniy. Do Regional Antibigrams (RA) Differ from Institutional Antibigrams (IA)? Presented at the 21st Annual Scientific Meeting of the Society of Healthcare Epidemiology (SHEA), April 1-4, 2011. Dallas, TX. [Abstract #373]
30. Boyd NK, Sliwinski J, Montoya MT, Walraven C, North M, **Mercier RC**. Comparison of Vancomycin (VAN) and Daptomycin (DAP) Susceptibilities and Outcomes for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia. Infectious. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 21 – 24, 2010. Vancouver, British Columbia, Canada. [Abstract #4424]
31. North M, Werth B, Sliwinski J, Deming P, Sakoulas G, **Mercier RC**. Relationship of microbiological and virulence characteristics to staphyloxanthin (STX) production in methicillin-resistant *Staphylococcus aureus* (MRSA). 2010 American College of Clinical Pharmacy Annual Meeting. Austin, TX. October 2010. [Abstract #147F]
32. Boyd NK, Richards E, Werth C, Young S, **Mercier RC**. Concerning Discrepancies in Linezolid and Daptomycin Susceptibility Reporting for *Enterococcus* spp. 2010 American College of Clinical Pharmacy Annual Meeting. Austin, TX. October 2010. [Abstract #22944]
33. Montoya MT, Yeaman MR, Bayer AS, **Mercier RC**. Diflunisal Decreases "Staphylococcus aureus" Colonization and Proliferation in an in vitro Model of Infective Endocarditis. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA. September 2010. [Abstract #E-1573]
34. Walraven CJ, North MS, **Mercier RC**. Disease state, not minimum inhibitory concentration (MIC), predicts vancomycin (VAN) failures. 50th Interscience Conference

- on Antimicrobial Agents and Chemotherapy. Boston, MA. September 2010. [Abstract #D-1515]
35. Vilay AM, Wong CS, Schrader RM, **Mercier RC**, Seifert SA. Acute kidney injury related to toxic exposures. *Pediatr Nephrol* 2010; 25: 52. Abstract presented at the International Pediatric Nephrology Association meeting in New York (Abstract #183).
 36. Kim J, **Mercier RC**, Boyd N, et al. Comparison between obese and non-obese patients in achieving target vancomycin concentrations [abstract]. In: University Healthcare Consortium (UHC) Pharmacy Council Meeting and the 44th Annual Meeting of the American Society of Health-system Pharmacists (ASHP); 2009 Dec 5-10; Las Vegas, NV.
 37. North M, Deming P, Hrebickova L, **Mercier R**. Clinical and microbiological outcomes associated with the pigment production of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia in hospitalized patients. 44th Annual American Society for Health-Systems Pharmacists. Las Vegas, NV. December 2009.
 38. Johnson B, **Mercier RC**, Thornton K, Veikley W, Hawkins T. Immunologic Response to Hepatitis B Vaccine in HIV-Infected Patients. Abstract #93. American College of Clinical Pharmacy Annual Meeting. Anaheim, CA. October 2009.
 39. Deming P, Werth B, Montoya M, Werth C, Sliwinski J, Young S, Sakoulas G, **Mercier RC**. Identification of MRSA strains as an independent risk factor in hospitalized patient outcome. American College of Clinical Pharmacy Annual Meeting. Anaheim, CA. October 2009.
 40. Boyd N, Young S, Deming P, **Mercier RC**, Werth CM. Assessment of methods for detecting reduced susceptibility to vancomycin for methicillin-resistant *Staphylococcus aureus* bacteremia. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2009.
 41. Werth C, Deming P, Montoya M, Sliwinski J, Young S, **Mercier RC**. Methicillin-resistant *Staphylococcus aureus* (MRSA): Comparison of methodologies to determine vancomycin (VAN) minimum inhibitory concentration (MIC) and correlation with clinical outcomes. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2009.
 42. **Mercier RC**, Graham, AC. 2009. Clinical Impact of an Adherence Intervention Program in HIV Patients. Presented at the 12th annual MAD, Making a Difference in Infectious Diseases Pharmacotherapy. May 7-10, Orlando, FL.
 43. Deming P, Young S, **Mercier RC**. 2009. Methicillin-Resistant *Staphylococcus aureus* (MRSA) Strains as an Independent Risk Factor in Hospitalized Patient Outcomes. Presented at the 12th annual MAD, Making a Difference in Infectious Diseases Pharmacotherapy. May 7-10, Orlando, FL.
 44. Pai MP, Samples M, **Mercier RC**. 2007. *Candida albicans* (CA) Biofilm Activity of Flucytosine (F), Liposomal Amphotericin B (L-AmB), and Micafungin (M) in an In Vitro Pharmacodynamic Model (PDM) of Simulated Endocardial Vegetations (SEVs). Presented at the 47th ICAAC, September 17-20, Chicago, IL.
 45. M. P. Pai, Samples M, **Mercier RC**. 2007. Activity of Flucytosine (F), Micafungin (M), and Voriconazole (V) in an In Vitro Pharmacodynamic Model (PDM) of *Candida* spp. (CS) Simulated Endocardial Vegetations (SEVs). Presented at the 47th ICAAC, September 17-20, Chicago, IL.
 46. Pai MP, Samples M, Mullen C, Apodaca A, Okoli N, **Mercier RC**. 2006. Ultrastructural (US) Characterization and Pharmacodynamic Evaluation of Flucytosine (F) and Voriconazole (V) in an In Vitro Model of *Candida* spp. (CS) infective Endocarditis (IE). Presented at the 46th ICAAC, September 27-30, San Francisco, CA.

47. Pai MP, Norenberg JP, Anderson T, Goade D, Rodvold, Telepak R, **Mercier RC**. 2006. Daptomycin (D) Pharmacokinetics (PK) in Morbidly Obese (MO) Subjects. Presented at the 46th ICAAC, September 27-30, San Francisco, CA.
48. Hrebickova L, Young S, DeCoster T, Dziamka P, Pai MP, **Mercier RC**. 2006. Safety and Disposition of Tobramycin (T) Impregnated (I) Polymethylmethacrylate (PMMA) Beads in Orthopedic Patients (OP) Presented at the 46th ICAAC, September 27-30, San Francisco, CA.
49. Dziamka P, Pai MP, Namdar R, Wright H, Young S, **Mercier RC**. 2005. Identification of MRSA Strains as an Independent Risk Factor in Hospitalized Patient Outcome. Mid-Year Meeting, American Society of Health Systems Pharmacy, Las Vegas, Nevada, December 2005.
50. Pai AB, Pai MP, Depczynski JC, McQuade C, **Mercier RC**. 2005. Effect of Non-Transferrin Bound Iron on Staphylococcus aureus Growth in Hemodialysis Patients Receiving Intravenous Iron Sucrose. Renal Week, American Society of Nephrology, Philadelphia, PA, November 2005.
51. Pai MP, Dietz RM, Jones AL, **Mercier RC**. 2003. Pharmacodynamic Evaluation of Once-daily Flucytosine (F) and Twice daily Voriconazole (V) in an In-Vitro Model of C. albicans (CA) Infective Endocarditis (IE). Presented at the 43rd ICAAC (Abstract No.M-1249), September 14-17, Chicago, IL.
52. Pai MP, **Mercier RC**. The Influence of pH on the Susceptibility of Candida Bloodstream isolates against fluconazole, itraconazole, and voriconazole. Presented at the 2002 Annual Meeting of the American College of Clinical Pharmacy (Abstract No. 154), October 19-23, Albuquerque, NM.
53. Graham AC, **Mercier RC**, Achusim L, Pai MP. Retrospective Analysis of Adverse Events Associated with Long-Term Antibiotic Therapy for Serious Gram-Positive Infections. Presented at the 2002 Annual Meeting of the American College of Clinical Pharmacy (Abstract No. 393), October 19-23, Albuquerque, NM.
54. **Mercier RC**, Wright H, Nadeau L, Nakano L, Arepally G, Koster F. 2002. Association Between Protease Inhibitors (PIs) and Thromboembolic Complications in HIV-Infected Patients. Presented at the 42nd ICAAC (Abstract No.H-1937), September 27-30, San Diego, CA.
55. **Mercier RC**, Mazzola JL, Dietz RM. 2002. Pharmacodynamic Evaluation of Tigecycline against Staphylococcus aureus (SA) in an In Vitro Model of Infective Endocarditis (IE). Presented at the 42nd ICAAC (Abstract No.A-500), September 27-30, San Diego, CA.
56. Dietz RM, Mazzola J, Yeaman MR, **Mercier RC**. 2002. Resistance to Thrombin-Induced Platelet Microbicidal Protein Confers a Competitive Advantage to Staphylococcus aureus in the Proliferation Stage of an In Vitro Model of Infective Endocarditis. Presented as a Poster and Platform at the 102th General Meeting of the American Society for Microbiology (Abstract No. B-361), May 19-23, Salt Lake City, UT.
57. Hawkins T, Geist C, Young B, Giblin A, **Mercier R**, Thornton K, Haubrich R. 2001. Efavirenz (EFV) Induced CNS Side Effects Persist for One Year Compared to Protease Inhibitors (PI's). Presented at the 41st ICAAC (Abstract No. I-1725), December 16-19, Chicago, IL.
58. **Mercier RC**, Dietz RM, Mazzola J, Bayer AS, Yeaman MR. 2001. Beneficial Effects of Thrombin-Stimulated Platelets Alone and in Combination with Vancomycin or Nafcillin in an In Vitro Model of Infective Endocarditis. Presented at the 41st ICAAC (Abstract No. B-783), December 16-19, Chicago, IL.
59. Alexov M, **Mercier RC**, Irizarry L. 2001. Evaluation of Macrolide Resistant Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model Simulating Intravenous Administration of Erythromycin. Presented at the 101th General Meeting of the American Society for Microbiology (Abstract No. A-133), May 20-23, Orlando, FL.

60. **Mercier RC**, Kennedy C, and Meadows C. 2000. Activities of GAR-936 Alone and in Combination versus Multi-Drug Resistant *Staphylococcus aureus* and *Enterococcus faecium*. Presented at the 40th ICAAC (Abstract No. 532), September 17-20, Toronto, Canada.
61. **Mercier RC**, Bayer AS, Sullam PM, Yeaman MR. 2000. *Enterococcus faecium* Circumvents the Antimicrobial Effects of Human Platelets in an In Vitro Model of Infective Endocarditis. Presented at the 40th ICAAC (Abstract No. 665), September 17-20, Toronto, Canada.
62. Louchahi K, **Mercier RC**, Nicholas P, Tod M, PetitJean O. 1999. A Procedure to Mimic Human Impaired Kinetic Profiles of Antibiotics with the Hollow Glass T-Tube In Vitro Pharmacodynamic Model. Presented at the 39th ICAAC (Abstract No. 2116), September 26-29, San Francisco, CA.
63. **Mercier RC**, Sullam PM, Bayer AS, Yeaman MR. 1999. Mechanisms by Which Platelets and Platelet Microbicidal Proteins Mediate Antibacterial Effects in an In Vitro Endocarditis Model of Infection. Presented at the 39th ICAAC (Abstract No. 1014), September 26-29, San Francisco, CA. and presented at the American College of Clinical Pharmacy 2000 Spring Practice and Research Forum (Abstract No. 69E), April 2-5, 2000, Monterey, CA
64. Bosso J, Bonapace C, White R, Friedrich L, Cappelletty D, **Mercier R**, Houlihan H, Aeschlimann J, Rybak M. 1998. Differences in antimicrobial effect determined with three in vitro pharmacodynamic models. Presented at the 38th ICAAC (Abstract No. A-134), September 24-27, San Diego, CA.
65. **Mercier RC**, Stumpo C, Rybak MJ. 1998. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, LY333328 against *Staphylococcus aureus* and *Enterococcus faecium*. Presented at the 38th ICAAC (Abstract No. F-118), September 24-27, San Diego, CA.
66. Rybak MJ, Cappelletty DM, Ruffing MJ, **Mercier RC**, Houlihan HH, Klepser ME, Levine DP. 1997. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections. Presented at the 37th ICAAC (Abstract No. A-46), September 28-October 1, Toronto, Canada.
67. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, **Mercier RC**, Rybak MJ. 1997. Comparative efficacy of trovafloxacin and vancomycin in the therapy of experimental methicillin-resistant *Staphylococcus aureus* endocarditis in rabbits. Presented at the 37th ICAAC (Abstract No. B-25), September 28-October 1, Toronto, Canada.
68. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, **Mercier RC**, Rybak MJ. 1997. Comparative efficacy of LY333328 and vancomycin in the therapy of experimental methicillin-resistant *Staphylococcus aureus* endocarditis in rabbits. Presented at the 37th ICAAC (Abstract No. F-11), September 28-October 1, Toronto, Canada.
69. **Mercier RC**, Yeaman MR, Bayer AS, Rybak MJ. 1997. In vitro interactions of platelets and *Staphylococcus aureus* strain pairs with differing intrinsic susceptibility to platelet microbicidal proteins. Presented at the 37th ICAAC (Abstract No. B-61), September 28-October 1, Toronto, Canada.
70. Houlihan HH, **Mercier RC**, McKinnon PS, Rybak MJ. 1997. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with gram-negative infection. Presented at the 37th ICAAC (Abstract No. A-42), September 28-October 1, Toronto, Canada.
71. **Mercier RC**, Rybak MJ. 1997. Pharmacodynamic evaluation of new glycopeptides using in vitro models of infection against methicillin-resistant *Staphylococcus aureus*. Presented at the 8th European Congress of Clinical Microbiology and Infectious Diseases (Abstract No. P395), May 25-28, Lausanne, Switzerland and presented at the

- American College of Clinical Pharmacy Annual Meeting (Abstract No. 202E), November 9-12, 1997, Phoenix, AZ.
72. Stokes DP, **Mercier RC**, Rybak MJ, Levine DP, Zervos MJ. 1997. Enterococcus faecalis (EF) small (SCV) and large colony variants (LCV). Presented at the 97th General Meeting of the American Society for Microbiology (Abstract No. D-102), May 4-8, Miami Beach, FL.
 73. **Mercier RC**, Rybak MJ. 1996. Effect of protein and concentration on the pharmacodynamic properties of a new glycopeptide, LY333328 (LY). Presented at the 36th ICAAC (Abstract No. F209), September 15-18, New Orleans, LA.
 74. **Mercier RC**, Houlihan HH, Rybak MJ. 1996. In vitro activity of a new glycopeptide, LY333328 (LY) alone and in combination with vancomycin (V), rifampin (R), and gentamicin (G) against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) at standard (SI) and high inoculum (HI). Presented at the 36th ICAAC (Abstract No. F206), September 15-18, New Orleans, LA.
 75. Rybak MJ, Houlihan HH, **Mercier RC**, Kaatz GW. 1996. Pharmacodynamics (PD) of RP 59500 (RP) (Quinupristin/Dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus infected fibrin-platelet clots in an in vitro infection model. Presented at the 36th ICAAC (Abstract No. A43), September 15-18, New Orleans, LA.
 76. Penzak SR, **Mercier RC**, Rybak MJ. 1996. In vitro activity of investigational antibiotics alone and in combinations against two strains of vancomycin-resistant Enterococcus faecium (VREF). Presented at the 36th ICAAC (Abstract No. F207), September 15-18, New Orleans, LA.
 77. Houlihan HH, **Mercier RC**, Rybak MJ. 1996. Pharmacodynamics (PD) of vancomycin (V) administered by intermittent infusion (I) versus continuous infusion (CI) alone and in combination with gentamicin (G) once daily (QD) or q 12h against methicillin-resistant Staphylococcus aureus (MRSA) in an in vitro infection model with simulated endocardial vegetations (SEV). Presented at the 36th ICAAC (Abstract No. A64), September 15-18, New Orleans, LA.
 78. Houlihan HH, **Mercier RC**, Rybak MJ. 1996. Evaluation of three different methods of susceptibility testing for RP 59500 quinupristin/dalfopristin (Synercid®): a new streptogramin antibiotic versus vancomycin. Presented at the American College of Clinical Pharmacy Annual Meeting (Abstract No. 85), August 4-7, Nashville, TN.
 79. **Mercier RC**, Houlihan HH, Rybak MJ. 1996. Evaluation of the bactericidal activity of new antibiotics against vancomycin-resistant Enterococcus faecium and faecalis. Presented at the American College of Clinical Pharmacy Annual Meeting (Abstract No. 75), August 4-7, Nashville, TN.
 80. Cappelletty DM, **Mercier RC**, Rybak MJ. 1995. Evaluation of the bactericidal and synergistic activity of a glycycline, CL 331,002 vs. Vancomycin, ofloxacin, minocycline, tetracycline against methicillin-resistant Staphylococcus aureus and vancomycin resistant Enterococcus faecium. Presented at the 35th ICAAC (Abstract No. I76), September 17-20, San Francisco, CA.

Invited Lectures and Presentations**Local/State**

1. **Mercier RC** 2020. HIV in Youth. CME Accredited presentation through AETC. Presented to UNM- AETC Grand Rounds. Zoom Presentation via ECHO platform to healthcare providers within South West region. November 6, 2020.
2. **Mercier RC** 2020. HIV ECHO. Presenter for five 1-hour session [Antiretroviral in Naïve Patients, OI prophylaxis, PEP to PrEP, PrEP Alternative Dosing & Drug Holidays in the era of social distancing during covid-19, PrEP for PWID]. CME Accredited sessions.
3. **Mercier RC** 2020. Syphilis and HIV PrEP. 1-hour presentation to faculty, residents, fellows and staff from Milagro Clinic. March 4, 2020. UNM-HSC Albuquerque, NM.
4. **Mercier RC** 2019. HIV Prevention Strategies: PEP & PrEP. CME Accredited presentation through AETC. Presented to Albuquerque Healthcare for the Homeless Healthcare Providers, December 4, 2019. Albuquerque, NM.
5. **Mercier RC** 2019. HIV Prevention Strategies: PEP & PrEP. CME Accredited presentation through AETC. Presented to First Nations healthcare providers, November 13, 2019. Albuquerque, NM.
6. **Mercier RC** and Young Adult Clinic Team. Young Adult Clinic at Truman. Summary of accomplishments and structure of the clinic presented to HRSA leadership and Operational Clinical Directors from Western Part of the US. October 18, 2019. Albuquerque, NM.
7. **Mercier RC** 2019. HIV ECHO. Presenter and/or Facilitator for five 1-hour session [Antiretroviral in Naïve Patients, OI prophylaxis, PEP to PrEP]. CME Accredited sessions.
8. **Mercier RC** 2019. HIV Patient Cases (Panel Discussion). New Mexico Annual HIV & HCV Update Conference, April 12, 2019. Albuquerque, NM.
9. **Mercier RC** 2018. HIV Patient Cases (Panel Discussion). New Mexico Annual HIV & HCV Update Conference, April 27, 2018. Albuquerque, NM.
10. **Mercier RC** 2018. Ready, Set, PrEP. New Mexico Nurse Practitioner Council Conference. April 27, 2018. Buffalo Thunder, Santa Fe, NM.
11. **Mercier RC**. 2018. HIV in Pregnancy. University of New Mexico Health Sciences Center Obstetrics and Gynecology Grand Rounds. March 9th, 2018. Albuquerque, NM.
12. **Mercier RC**. 2017. HIV Update to Include Latest Antiretrovirals. New Mexico Health Resources, Inc. 25th Annual Health Provider Retreat. June 16, 2017. Taos, NM
13. **Mercier RC** 2017. Ready, Set, PrEP. University of New Mexico Health Sciences Center Internal Medicine Grand Rounds, May 18, 2017. Albuquerque, NM.
14. **Mercier RC** 2017. HIV Patient Cases (Panel Discussion). New Mexico Annual HIV & HCV Update Conference, May 5, 2017. Albuquerque, NM.
15. **Mercier RC** 2016. Ready, Set, PrEP. 22nd Annual Four Corners TB/HIV Conference. November 17, 2016. ACPE accredited. Flagstaff, AZ.
16. **Mercier RC** 2016. Ready, Set, PrEP. NMSHP Balloon Fiesta Symposium. October 3, 2016. ACPE accredited. Albuquerque, NM.
17. **Mercier RC** 2016. Ready, Set, PrEP. Western Medicaid Pharmacy Administrators Association Meeting. September 8, 2016. Santa Fe, NM.
18. **Mercier RC** 2016. Ready, Set, PrEP. 87th NMPHA Annual Convention HAART. June 25, 2016. ACPE#:0104-0000-16-035-L01-P. Albuquerque, NM.
19. **Mercier RC** 2016-2017. HIV ECHO. Presenter and Facilitator for five 1-hour session [Antiretroviral Toxicity, HAART Drug Interactions, OI prophylaxis], HAART experienced patient, HAART Pregnant patients]. CME Accredited sessions.

20. **Mercier RC** 2015-2016. HIV ECHO. Presenter and Facilitator for five 1-hour session [Antiretroviral Toxicity, HAART Drug Interactions, OI prophylaxis], HAART experienced patient, HAART Pregnant patients]. CME Accredited sessions.
21. **Mercier RC** 2015. Sex in the City. 86th NMPHA Annual Convention. June 27, 2015. ACPE# 0104-0000-15-031-L01-P. Albuquerque, NM.
22. **Mercier RC** 2014-2015. HIV ECHO. Presenter and Facilitator for five 1-hour session [Antiretroviral Toxicity, HAART Adherence, HAART Drug Interactions, OI prophylaxis]. CME Accredited sessions.
23. **Mercier RC** 2013-2014. HIV ECHO. Presenter and Facilitator for four 1-hour session [Antiretroviral Toxicity, HAART Adherence, HAART Drug Interactions, Dyslipidemia in HIV]. CME Accredited sessions.
24. **Mercier RC** Fall 2012. Hepatitis C ECHO Clinic. Medication Adherence. CME accredited 1-hour session.
25. **Mercier RC** 2012-2013. HIV ECHO. Presenter and Facilitator for three 1-hour session [Antiretroviral Toxicity, HAART Adherence, Dyslipidemia in HIV]. CME Accredited sessions.
26. **Mercier RC** 2011-2012. HIV ECHO. Presenter and Facilitator for three 1-hour session [Antiretroviral Toxicity, HAART Adherence, Dyslipidemia in HIV]. CME Accredited sessions.
27. **Mercier RC** 2010. Alternative & Complementary Medicines: a discussion with consumers. Presentation at the New Mexico AIDS Services for Consumers. May 4, 2010. Albuquerque, NM.
28. **Mercier RC** 2008. MRSA: Today and Tomorrow. Presentation for the NMSHP Dinner Symposium Series. ACPE accredited. June 18, 2008. Albuquerque, NM.
29. **Mercier RC** 2008. Daptomycin Clinical Use. Dinner Presentation to Physicians, nurses and other health care providers. February 21, 2008. Albuquerque, NM.
30. **Mercier RC** 2008. New Treatment Approaches for HIV. AETC presentation for Pharmacists in Northern New Mexico Medical Center. ACPE#104-999-07-016-L02. January 30, 2008. Shiprock, NM
31. **Mercier RC** 2007. New Treatment Approaches for HIV. Presentation for American Pharmaceutical Association Annual Meeting. ACPE#104-999-07-016-L02. June 24, 2007. Albuquerque, NM
32. **Mercier RC** 2007. Daptomycin Clinical Use. Dinner Presentation to Physicians, nurses and other health care providers. June 13 2007. Santa Fe, NM.
33. **Mercier RC** 2007. New Treatment Approaches for HIV. AETC Dinner presentation for Pharmacists. ACPE#104-999-07-016-L02. April 10, 2007. Albuquerque, NM
34. **Mercier RC** 2007. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Dinner Presentation given to Las Cruces Health Care Providers. March 22, 2007. La Mesilla, NM.
35. **Mercier RC** 2007. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Lunch Presentation given to Memorial Hospital Health Care Providers. March 22, 2007. Las Cruces, NM.
36. **Mercier RC** Case Studies Presentation. Dinner Discussion Leader for Health Care Providers. March 13th, 2007. Albuquerque, NM.
37. **Mercier RC** 2007. Daptomycin Microbiology Testing. Dinner Presentation to NM Microbiologists. February 28, 2007. Albuquerque, NM.
38. **Mercier RC** 2006. Outpatient Use of Antibiotics. Internal Medicine Grand Rounds, CME activity presented for St. Vincent Hospital. August 29, 2006. Santa Fe, NM.
39. **Mercier RC** 2006. Tigecycline, a new therapeutic approach. Dinner symposium presented for Surgeons. December 12, 2006. Farmington, NM.

40. **Mercier RC** 2006. Tigecycline, a new therapeutic approach. Lunch symposium presented for UNM ID physicians. August 14, 2006. Albuquerque, NM.
41. **Mercier RC** 2006. Tigecycline, a new therapeutic approach. Lunch symposium presented for UNM Surgery physicians. August 9, 2006. Albuquerque, NM.
42. **Mercier RC** 2006. Judicious use of antibiotics in hospital-acquired pneumonia. Lunch symposium presented for the San Juan Nephrology group. April 3, 2006. Farmington, NM.
43. **Mercier RC** 2006. Tigecycline, a new therapeutic approach. Lunch symposium presented for St. Vincent Hospital Pharmacy and Hospitalists Groups. February 2, 2006. Santa Fe, NM.
44. **Mercier RC** 2006. Judicious use of antibiotics in hospital-acquired pneumonia. Lunch symposium presented at Southwest Pulmonary. January 31, 2006. Albuquerque, NM.
45. **Mercier RC** 2006. Appropriate use of antibiotics in the hospital. Lunch presentation given to the DOP at Presbyterian Hospital. January 4, 2006. Albuquerque, NM.
46. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Dinner Presentation given to Albuquerque ID specialists. December 13, 2005. Albuquerque, NM.
47. **Mercier RC** 2005. Judicious use of antibiotics in hospital-acquired pneumonia. Lunch symposium presented at San Juan Regional Medical Center. November 30, 2005. Farmington, NM.
48. **Mercier RC** 2005. Tigecycline, a new therapeutic approach. Lunch symposium presented for NM Surgical Associates. November 29, 2005. Albuquerque, NM.
49. **Mercier RC** 2005. Judicious use of antibiotics in hospital-acquired pneumonia. Dinner symposium presented at Presbyterian Hospital for health care professionals. November 16, 2005. Albuquerque, NM.
50. **Mercier RC** 2005. Tigecycline, a new therapeutic approach. Lunch symposium presented for ID Associates. November 8, 2005. Albuquerque, NM.
51. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Lunch symposium presented at the UNM Surgery group. October 12, 2005. Santa Fe, NM.
52. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Presentation given at the UNM surgery grand rounds. October 7, 2005. Albuquerque, NM.
53. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Presentation at the Annual Balloon Fiesta NMSHP meeting. ACPE Program October 3, 2005. Albuquerque, NM.
54. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Lunch symposium presented at the St-Vincent Hospital for health care professionals. September 14, 2005. Santa Fe, NM.
55. **Mercier RC** 2005. Judicious use of antibiotics in hospital-acquired pneumonia. Lunch symposium presented at ARMC for health care professionals. August 12, 2005. Albuquerque, NM.
56. **Mercier RC** 2005. Treatment associated Clostridium difficile diarrhea. Dinner presentation for the surgeons. June 29, 2005. Roswell, NM.
57. **Mercier RC**, Hrebickova L. 2005. Antiretrovirals: managing side effects and drug interactions. Presented at the 4th Annual HMA HIV/AIDS Treatment Conference. June 17, 2005. Santa Fe, NM.
58. **Mercier RC** 2005. Judicious use of antibiotics in hospital-acquired pneumonia. Lunch symposium presented at Lovelace Medical Center for health care professionals. June 14, 2005. Albuquerque, NM.

59. **Mercier RC** 2005. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Lunch symposium presented at the VA Medical Center for health care professionals. May 12, 2005. Albuquerque, NM.
60. **Mercier RC, L. Hrebickova.** Antiretroviral drugs: a focus on adverse events and drug interactions. Presented for the clinic staff at the Truman Street Clinic. April 28, 2005. Albuquerque, NM.
61. **Mercier RC** 2004. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to VRE. Grand Rounds presented at the Heart Hospital of New Mexico. May 21, 2004. Albuquerque, NM. Dinner presentation for the ID specialists and pharmacist. December 2, 2004. Albuquerque, NM.
62. **Mercier RC** 2004. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Grand Rounds/CME presented at the San Juan Regional Medical Center. October 20, 2004. Farmington, NM.
63. **Mercier RC** 2004. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Dinner presentation for the ID specialists. August 17, 2004. Farmington, NM.
64. **Mercier RC** 2004. Back to Basics with Antibiotics. NMPHA Annual Convention. ACPE Program # 104-000-04-017-L01. June 19, 2004. Albuquerque, NM.
65. **Mercier RC** 2004. Emerging Resistance in Gram-Positive Cocci, A Clinical Approach to MRSA. Grand Rounds presented at the Heart Hospital of New Mexico. May 21, 2004. Albuquerque, NM.
66. **Mercier RC** 2004. Antiviral/retroviral therapy. One hour lecture presented to the 2nd year medical students as part of the Transition block. UNM – SOM, Albuquerque, NM. March 10, 2004.
67. **Mercier RC** 2004. The Role of Gatifloxacin in the Treatment of Indicated Bacterial Infections. Dinner symposium for Health Care Professionals in Northern New Mexico. March 18, 2004. Taos, NM.
68. **Mercier RC** 2004. The Battle Against Gram-Positive Infections. Dinner Symposium for NMSHP. ACPE Program # 176-000-04-001-L01. January 22, 2004. Albuquerque, NM.
69. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at St. Vincent Hospital. August 21, 2003. Santa Fe, NM.
70. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at Kindred Hospital. August 13, 2003. Albuquerque, NM.
71. **Mercier RC** 2003. Emerging Trends in the Management of Acute Respiratory Tract Infections. Dinner Symposium for ID specialists and Pharmacists. ACPE Program # 104-999-03-032-L01. August 11, 2003. Albuquerque, NM.
72. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at San Juan County Medical Center. July 23, 2003. Farmington, NM.
73. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at Albuquerque Medical Center. July 21, 2003. Albuquerque, NM.
74. **Mercier RC** 2003. The Role of Gatifloxacin in the Treatment of Indicated Bacterial Infections. Lecture presented at Grand Rounds at Indian Health Hospital. July 9, 2003. Santa Fe, NM.
75. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at Presbyterian Hospital. July 7, 2003. Albuquerque, NM.
76. **Mercier RC** 2003. An Update on the Management of Complicated Intra-Abdominal Infections. Dinner Symposium for ID specialists and Pharmacists in Clovis, NM. May 28, 2003.
77. **Mercier RC** 2003. An Update on the Management of Complicated Intra-Abdominal Infections. Lunch Symposium for ID specialists and Pharmacists in Roswell, NM. May 28, 2003.

78. **Mercier RC** 2003. Bacterial Resistance and Clinical Consequences. Lunch Symposium at Lovelace Health Systems Hospital. April 11, 2003. Albuquerque, NM.
79. **Mercier RC** 2003. Sexually Transmitted Diseases and HIV. Lecture (3 hours) presented to the Biology of Sex class at TVI Community College. April 9, 2003. Albuquerque, NM.
80. **Mercier RC** 2003. An Update on the Management of Complicated Intra-Abdominal Infections. Dinner Symposium for ID specialists and Pharmacists in Santa Fe, NM. February 19, 2003.
81. **Mercier RC** 2003. HIV therapy. Ninety minute lecture presented to the 2nd year medical students as part of the Transition block. UNM – SOM, Albuquerque, NM. February 13 and 18 2003.
82. **Mercier RC** 2002. Emerging Trends in the Management of Acute Respiratory Tract Infections. Dinner Symposium for ID specialists and Pharmacists. November 25, 2002. Albuquerque, NM.
83. **Mercier RC** 2002. Bacterial Resistance & Clinical Consequences. Department of Pharmacy. University of New Mexico – Health Sciences Center. September 20, 2002, Albuquerque, NM.
84. **Mercier RC** 2002. Bacterial Resistance & Clinical Consequences. Department of Pharmacy. VA Medical Center. September 19, 2002, Albuquerque, NM.
85. **Mercier RC** 2002. Clinical Consequences of Bacterial Resistance & Potential Solutions. New Mexico Pharmaceutical Association Monthly Meeting. ACPE #104-000-02-017-L01. June 19, 2002, Albuquerque, NM.
86. **Mercier RC** 2002. An Update on the Management of Complicated Intra-Abdominal Infections. Dinner Symposium for ID specialists and Pharmacists. June 4, 2002, Albuquerque, NM.
87. **Mercier RC** 2002. Strategies for Quinolone Use. New Mexico Pharmaceutical Association Annual Meeting. ACPE #104-000-01-032-L01. January 20, 2002, Albuquerque, NM.
88. **Mercier RC** 2001. Clinical Consequences of Gram-Positive Resistance and Potential Solutions. Internal Medicine Grand Rounds, Taos Hospital. July 14, 2001, Taos, NM.
89. **Mercier RC** 2001. To Nuc or Not? University of New Mexico – School of Medicine, Department of Internal Medicine, HIV clinic (Attendings, residents and medical students). June 22, 2001, Albuquerque, NM.
90. **Mercier RC** 2001. Review of Antiretroviral Therapy. University of New Mexico – School of Medicine, Department of Internal Medicine (Attendings, residents and medical students). June 14, 2001, Albuquerque, NM.
91. **Mercier RC** 2001. Antiretroviral Therapy and Adherence. New Mexico AIDS Service. (Clients, Case managers, Social Workers). May 10, 2001, Albuquerque, NM.
92. **Mercier RC** 2000. Advances in Antiretroviral Therapy. Update and Review of Internal Medicine 2000. Harvard Medical School and the University of New Mexico – School of Medicine Continuing Education Program. October 15-20, 2000, Santa Fe, NM.
93. **Mercier RC** 2000. Review of Antimicrobial Agents. University of New Mexico – School of Medicine, Department of Urology (Attendings, residents and medical students). September 1, 2000, Albuquerque, NM.
94. **Mercier RC** 2000. Achieving Optimal Outcome in the Treatment of Infections through Better Understanding of Antibiotic Pharmacokinetics. New Mexico Infectious Disease Potpourri X. June 16, 2000, Albuquerque, NM.
95. **Mercier RC** 2000. The Challenges of HIV Therapy: New Strategies and New Issues. ACPE #176-000-00-048-L-02. May 24, 2000, Albuquerque, NM.
96. **Mercier RC** 1999. The Rationale Use of Intravenous Antibiotics in the Home Care Setting. University of New Mexico Home Health Care. Albuquerque, NM.

97. **Mercier RC** 1999. Vaccine Science and Practice. Implementing a Community Pharmacy Immunization Program. Continuing Education Program. Albuquerque, NM.
98. **Mercier RC** New Mexico Society of Health-System Pharmacists, 1999 Annual Balloon Fiesta Meeting. Responsible for presenting a Clinical Pearl as a faculty member of the College of Pharmacy entitled: The new era of antiretrovirals.
99. Goade D, Rabinowitz I, **Mercier RC**. 1999. Drug Reactions and Eosinophilia. Clinical Pathology Conference (CPC). University of New Mexico – School of Medicine. Albuquerque, NM.
100. Mertz GJ, **Mercier RC**. 1999. Single Daily Dosing of Aminoglycosides. Internal Medicine Grand Rounds, University of New Mexico – School of Medicine. Albuquerque, NM.
101. **Mercier RC** 1999. The importance of HIV adherence. New Mexico AIDS Services (NMAS) Annual Meeting. Expert consultant in a panel discussion. Capitan, NM.
102. **Mercier RC** New Mexico Society of Health-System Pharmacists, 1998 Annual Balloon Fiesta Meeting. Responsible for presenting a Clinical Pearl as a faculty member of the College of Pharmacy entitled: The emergence of vancomycin-resistant *Enterococcus faecium* and the arrival of a new drug, Synercid®.
103. **Mercier RC**, Beeley P. 1998. Intravenous Immunoglobulins: uses in the outpatient and home care setting. Intravenous Nurses Society, New Mexico Chapter. Albuquerque, NM.
104. **Mercier RC** 1998. Rationale Use of Antimicrobials. Physician Assistant Program, University of New Mexico. Albuquerque, NM.
105. **Mercier RC** 1998. Antimicrobial Management of the Immunocompromised Patient. Graduate Nursing Program, University of New Mexico. Oncology Nursing Pharmacology Class. Albuquerque, NM.
106. **Mercier RC** 1996. Pharmacodynamic evaluation of LY333328, a new glycopeptide against MRSA and VREF. Fourth Annual Inter-University Research Fellowship Forum. Dearborn, MI. Sponsored by Wayne State University.

National/International

1. **Mercier RC**, Tung E, Newsome C. PrEParing Pharmacists to Prevent HIV. ACPE Accredited Activity #: 0204-0000-20-221-L02-P; Activity #: 0204-0000-20-221-H02-P. Presented at the American Society Health System Pharmacist MidYear meeting via Zoom. December 6, 2020.
2. **Mercier RC**. 2016. Baylor ECHO. Ready, Set, PrEP. CE Accredited. November 30, 2016. Houston, TX. (Conducted via teleconferencing).
3. **Mercier RC**. 2016. 22nd Annual Four Corners TB and HIV Conference. PrEP Talk. CE Accredited. November 17, 2016. Flagstaff, AZ.
4. **Mercier RC** 2011. Medical Errors that Can Break the HAART. Presentation at the Mountain Plains AIDS Education and Training Center. CME accredited presentation. August 11, 2011. Denver, CO.
5. **Mercier RC** 2011. Hepatitis C. Presentation at the annual MAD, Making a Difference in Infectious Diseases Pharmacotherapy. ACPE accredited presentation. May 12, 2011. Orlando, FL.
6. **Mercier RC** 2009. Viral Hepatitis Update: The Changing Spectrum of Disease. Presentation at the annual MAD, Making a Difference in Infectious Diseases Pharmacotherapy. ACPE accredited presentation. May 7, 2009. Orlando, FL.
7. **Mercier RC** 2009. Stewardship: Swap Meet. Presentation at the annual MAD, Making a Difference in Infectious Diseases Pharmacotherapy. Antimicrobial Stewardship Workshop Leader. May 6, 2009. Orlando, FL.

8. **Mercier RC** 2007. Pharmacoeconomics of Linezolid in Gram-Positive Infections. Presentation at Pfizer National Speakers Bureau. December, 2007. Dallas, TX.
9. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Dinner presentation to Health Care Providers. September, 2007. Las Vegas, NV
10. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Dinner presentation to Health Care Providers. August, 2007. Phoenix, AZ
11. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Dinner presentation to Health Care Providers. July, 2007. Tuscon, AZ
12. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Dinner presentation to Health Care Providers. June 27, 2007. Killeen, TX
13. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Lunch presentation to Health Care Providers. June 27, 2007. Waco, TX
14. **Mercier RC** 2007. The Challenges with Methicillin-Resistant Staphylococcus aureus. Dinner presentation to Health Care Providers. June 26, 2007. Dallas/Forth Worth, TX.
15. **Mercier RC** 2005. Tigecycline, a new therapeutic approach. Dinner symposium presented for Good Samaritan Hospital Surgery Group. November 2, 2005. Phoenix, AZ.
16. **Mercier RC** 2005. Herbal medicines: entering the abyss.. Presentation given for HIV healthcare providers at the Annual Mountain West AIDS Education and Training meeting. August 5, 2005. Keystone, CO.
17. **Mercier RC** 2003. Evaluating the Clinical Literature in ID. Making a Difference Conference. ACPE #061-999-03-056-L01. May 4, 2003. Orlando, FL.
18. **Mercier RC** 2002. An Update on the Management of Complicated Intra-Abdominal Infections. Lunch Symposium in Farmington, NM and Dinner Symposium for ID specialists and Pharmacists in Durango, CO. December 12, 2002.
19. **Mercier RC** 2002. An In Vitro Model of Endovascular Infection to Study Microbial Pathogenesis and Treatment Strategies. In symposium: 254/A Biofilms, Tolerance, and Resistance at the Site of Infection at the 102th General Meeting of the American Society for Microbiology, May 19-23, Salt Lake City, UT.
20. **Mercier RC** 1997. In vitro interaction of platelets and Staphylococcus aureus strain pairs with differing intrinsic susceptibility to platelet microbicidal proteins. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada.
21. **Mercier RC** 1997. In vitro interaction of platelets and Staphylococcus aureus strain pairs with differing intrinsic susceptibility to platelet microbicidal proteins. Society of Infectious Diseases Pharmacists Annual Meeting. Toronto, Canada.
22. **Mercier RC** 1997. In vitro interaction of platelets and Staphylococcus aureus strain pairs with differing intrinsic susceptibility to platelet microbicidal proteins. Fifth Annual Inter-University Research Fellowship Forum. Minneapolis, MN. Sponsored by the University of Minnesota.
23. **Mercier RC** 1997. Levofloxacin: a review. Blue Cross/ Blue Shield Health Care Manage System. Cincinnati, OH.
24. **Mercier RC** 1996. Evaluation of the bactericidal activity of new antibiotics against vancomycin-resistant Enterococcus faecium and faecalis. American College of Clinical Pharmacy Annual Meeting. Nashville, TN.

Teaching Experience (Contact Hours)

Wayne State University

BSc. in Pharmacy Program
Instructor

Infectious Diseases Therapeutics, PHA-421. Winter 1996, (6 hours); Winter 1997, (6 hours). .

Pharm.D. Program

Instructor

Diseases Process and Therapeutics, Infectious Diseases section, PPR-662. Fall 1995, (5 hours); Fall 1996, (5 hours).

University of New Mexico

BSc. in Pharmacy Program

Instructor

Therapeutic Drug Monitoring, PHARM-437. Fall 1997, (1 hour).
Pharmacology III, PHARM-476. Spring 1998, (3 hours).

Instructor & Module Coordinator

Pharmacotherapy II, PHARM 432. Spring 1999, (18 hours).

Pharm.D. Program

Instructor - Prepare and deliver lectures, write exam questions, attend exam and graded exam reviews. When appropriate attend and conduct laboratory sessions.

Integrated Pharmacotherapy IV, PHRM 835.

Spring 2019 (Developed new course, taught 14 hours); Spring 2020
(Taught/exam 14 hours)

Integrated Pharmacotherapy V, PHRM 840.

Fall 2018 (Developed new course, taught 9 hours); Fall 2019 (Taught/Exam 10
hours); Fall 2020 (Taught/Exam 9 hours)

Aspect of Patient Care Lab (PHRM843L).

Fall 2019 (HIV Integration week; developed lab activities and facilitated; 3 hours);
Fall 2020 (HIV Integration week; developed lab activities and facilitated; 6 hours)

Integrated Pharmacotherapy III, PHRM 830.

Spring 2018 (Developed new course, taught 21 hours), Spring 2019 (8 hours)
Aspect of Patient Care Lab (PHRM833L).

Spring 2018, Spring 2019 (ID integration week, vancomycin week, ID charts; 21
hours)

Pathophysiology, PHARM-705, PHARM-805

Fall 2001 (2 hours), Fall 2002 (3 hours), Fall 2004 (2.5 hours), Fall 2005 (3
hours), Fall 2006 (3 hours), Fall 2007 (3 hours), Fall 2008 (3 hours), Fall 2009 (3
hours), Fall 2010 (3 hours), Fall 2016 (2 hours), Fall 2017 (2 hours), Fall 2018 (2
hours), Fall 2019 (2 hours).

Mechanisms of Drug action, PHARM-732. Spring 1998, (2 hours), Spring 2007 (1 hour),
Spring 2008 (1 hour), Spring 2009 (1 hours), Spring 2011 (2 hours), Spring 2012
(2 hours), Spring 2013 (2 hours), Spring 2014 (2 hours), Spring 2015 (2 hours),
Spring 2016 (3 hours), Spring 2017 (2 hours).

Pharmaceutical Care Laboratory, PHARM-762L. Fall 2016 (12 hours), Fall 2017 (PBL
week and vancomycin week, 14 hours)

Pharmacotherapy I, PHARM-751.

Fall 2001 (26 hours), Fall 2008 (26 hours), Fall 2009 (32 hours), Fall 2010 (30 hours), Fall 2011 (30 hours), Fall 2012 (34 hours), Fall 2013 (37 hours), Fall 2014 (38 hours), Fall 2015 (36 hours), Fall 2016 (35 hours), Fall 2017 (31 hours).
Pharmacotherapy II, Infectious Diseases Module, PHARM-752.
Spring 1999 (18 hours); Spring 2000 (19 hours); Spring 2001 (26 hours); Spring 2003 (23 hours); Spring 2004 (18 hours), Spring 2005 (23 hours), Spring 2006 (17 hours), Spring 2007 (22 hours), Spring 2008 (24 hours).
Physical Assessment and Clinical Skills, PHARM-750.
Spring 1999, Spring 2000 (12 hours), Spring 2002 (12 hours), Spring 2007 (12 hours), Spring 2007 (12 hours +), Spring 2008 (12 hours), Fall 2008 (27 hours), Fall 2009 (40 hours).
Clinical Pharmacokinetics, PHARM-745.
Fall 1998 (6 hours); Fall 1999 (7 hours); Fall 2000 (7 hours); Fall 2001 (5 hours); Fall 2002 (5 hours).
Student-Centered, Problem-Based Learning, PHARM-711/721/741 (6 hours/week X 8 weeks).
Fall 1998, Fall 1999, Fall 2000, Fall 2001, Fall 2002.
Student-Centered, Problem-Based Learning, PHARM-712/722 (6 hours/week X 8 weeks).
Spring 1998, Spring 1999, Spring 2000, Spring 2001, Fall 2001, Spring 2002, Spring 2003, Spring 2004, Spring 2005.
Practice Patient Experience, PHARM-716 (6 hours/week X 8 weeks).
Spring 1998-2005.
Advanced Therapeutics, PHARM 788. Spring 1998, (15 hours).
Therapeutic Drug Monitoring, PHARM-784. Fall 1997, (1 hour).

Course Master – Responsible for case rewrite assignments and coordination of PHARM-741

Student-Centered, Problem-Based Learning, PHARM-741. Wrote all original PHARM-741 Infectious Diseases Cases (7 cases). Summer 1998. Fall 2002.

Module Coordinator - Responsible for schedule coordination, exam preparation and administration, key assessment, and test question challenges.

Infectious Diseases Module, Pharmacotherapy I & II, 751 & 752.
Spring 1999, Spring 2000, Spring 2001, Fall 2001, Spring 2003-2008, Fall 2008-2011, Fall 2014, Fall 2016, Fall 2017.

Course Coordinator, Instructor of Record – Designed the courses and objectives. Coordinate the classes, oversees exam and grades. Responsible for the overall syllabus and good administration of the course. Provide lectures and learning activities.

Integrated Pharmacotherapy III, PHRM 830. Instructor of Record.
Spring 2018, Spring 2019. (6 hours per week X 8 weeks)
Integrated Pharmacotherapy IV, PHRM 835. Instructor of Record.
Spring 2018, Spring 2019. (6 hours per week X 8 weeks), Spring 2020 (help complete semester due to IOR on leave)
Clinical Pharmacokinetics, PHARM-745 (3 hours/week X 17 weeks).
Fall 1998, 1999, (Co-coordinator) 2000, 2001, 2002.

Infectious Diseases Elective, PHARM-784 (2 hours/week X 8 weeks)

Spring 2009 (9 students), Spring 2010 (31 students), Spring 2011 (28 students), Spring 2012 (28 students), Spring 2013 (31 students), Spring 2014 (41 students), Spring 2015 (31 students), Spring 2016 (46 students), Spring 2017 (28 students), Spring 2020.

Pharmaceutical Care Laboratory, PHARM-762L (up to 8 hours per week X 14 weeks).

Fall 2015 (86 contact hours in class or lab and 7 hours in OSCE).

Preceptor – Design, conduct the rotation, meet with students, round in the hospital, provide education to students and medical team, attend student presentations and provide feedback and grades.

Clinical Clerkship, PHARM-786 & 770 (40 hours/week X 4 weeks).

1998 (12 students), 1999 (15 students), 2000 (18 students), 2001 (18 students), 2002 (6 students), 2003 (12 students), 2004 (10 students), 2005 (6 students, 4 residents), 2006 (7 students, 6 residents), 2007 (8 students, 3 residents), 2008 (6 students, 5 residents), 2009 (5 students, 13 residents), 2010 (3 students, 6 residents), 2011 (4 students, 3 residents), 2012 (6 students, 2 residents), 2013 (6 students, 5 residents), 2014 (8 students, 5 residents), 2015 (2 students, 7 residents), 2016 (4 students, 3 residents), 2017 (6 students, 8 residents), 2018 (4 students, 3 residents), 2019 (6 students, 6 residents)

School of Medicine Graduate Program Degree

BIOM 555 Responsible Conduct of Research (Ethics).

Provided 2 hour on Conflict of Interest in Research. Fall 2016, Spring 2017, Fall 2017, Fall 2018, Spring 2019.

School of Medicine M.D. Degree

Instructor – 2nd year Infectious Diseases Module, provide lecture to the medical students during the Infectious Diseases teaching module (1 hour/lecture topic)

Fall 2011 (Antiviral drugs; 1 hour), Fall 2012

(Pharmacokinetic/Pharmacodynamics, Bacterial Resistance, Antiviral Drugs; 3 hours), Fall 2013 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs, Resistance in Gram-negative; 4 hours), Fall 2014 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours), Fall 2015 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours), Fall 2016 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours), Fall 2017 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours), Fall 2018 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours), Fall 2019 (Antibiotic Overview, Concept in Antimicrobial Resistance, Antiviral Drugs; 3 hours).

Instructor – 1st year Infectious Diseases Module, provide lecture to the medical students during the Infectious Diseases teaching module (1 hour/lecture topic)

Spring 2020 (Antibiotic Overview, Concept in Antimicrobial Resistance; 2 hours)

School of Medicine Infectious Diseases Fellowship/ ID Division

Lecturer – Provide lectures on Infectious Diseases Pharmacy Related topics (1 hour/lecture topic) to the Fellows and Faculty from the School of Medicine

Division of Infectious Diseases

Fall 2006 (3 hours), Fall 2007 (2 hours), Fall 2008 (3 hours), Fall 2009 (3 hours), Fall 2010 (4 hours), Fall 2011 (4 hours), Fall 2012 (4 hours), Fall 2013 (2 hours), Fall 2014 (2 hours), Spring 2015 (2 hours), Spring 2016 (2 hours)

Physician Assistant Program

Lecture – Provide the Infectious Diseases lectures to the 1st year PA students, wrote the assessment questions

Fall 2013 (6 hours), Fall 2014 (5 hours), Fall 2016 (2 hours), Fall 2017 (2 hours)

Post-Doctorate Pharmacy Training Program

Director/Coordinator - Specialized Residency in Ambulatory Care Pharmacotherapy.

Developed and organized a 1-year training program in ambulatory care within the Truman Health Services Clinic. The program provides the resident with extensive clinical experience in all areas of Ambulatory Care. The resident has opportunities for elective rotations within the inpatient setting of UNMH. Additionally, the resident gains research experience by designing, conducting and analyzing a study. The residency is offered at the University of New Mexico – Health Sciences Center, Truman Health Services clinic. The first resident began training in July 2020.

Residents Completion Dates	Current Position
1. Mark Cinquegrani July 2020 - June 2021	

Director/Coordinator - Specialized Residency in Infectious Diseases Pharmacotherapy.

Developed and organized a 1-year training program in infectious diseases. The program provides the resident with extensive clinical experience in all areas of infectious diseases. Additionally, the resident gains research experience by designing, conducting and analyzing a study. The residency is offered at the University of New Mexico – Health Sciences Center. The first resident began training in July 1999.

Residents Completion Dates	Current Position
2. Heather N. Wright July 1999 - June 2000	Pharmacist Presbyterian Rush Hospital Albuquerque, NM
3. Lynn M. Nadeau July 2000 - June 2001	Clinical Pharmacist - Infectious Diseases Hotel-Dieu Grace Hospital Windsor, Ontario, Canada
4. Lara H. (Nakano) Gomez July 2001 – June 2002	Director of Clinical Education University of Hawaii, College of Pharmacy Hilo, HI
5. Agatha C. Graham July 2002 – June 2003	
6. Katherine E. Werner July 2003 – June 2004	Clinical Coordinator VA Portland Health Care System Portland, OR

7. Lenka Hrebickova July 2004 – June 2005	Clinical Pharmacist University Hospital San Antonio, TX
8. Paulina (Dziamka) Deming July 2005 – June 2006	Associate Professor of Pharmacy University of New Mexico College of Pharmacy Albuquerque, NM
9. Jasmina Demirovic July 2006 – June 2007	Clinical Coordinator St-Vincent Hospital Santa Fe, NM
10. Natalie Boyd July 2008 – June 2009	PhD Graduate Students - Translational Science University of Texas at San Antonio San Antonio, TX
11. Bernadette (Johnson) Jakeman July 2008 – June 2009	Assistant Professor of Pharmacy University of New Mexico College of Pharmacy Albuquerque, NM
12. Carla Walraven July 2009 -June 2010	Antimicrobial Stewardship Clinical Pharmacist University Hospitals Albuquerque, NM
13. Michael North July 2010 -June 2011	Infectious Diseases Pharmacists Centura Health Englewood, CO
14. Thomas Dilworth July 2011 – June 2012	Clinical Pharmacy Supervisor, Infectious Disease Pharmacist Wheaton Franciscan - St-Francis Hospital Milwaukee, WI
15. Melinda Montoya July 2012 – June 2013	Pharmacist University Hospitals Albuquerque, NM
16. Larry Pineda July 2013 - June 2014	Visiting Assistant Professor of Pharmacy University of New Mexico College of Pharmacy Albuquerque, NM
17. Brandon Dionne July 2014 – June 2015	Clinical Assistant Professor Midwestern University College of Pharmacy Glendale, AZ
18. Keenan Ryan July 2015 – June 2016	Antimicrobial Stewardship Clinical Pharmacist University Hospitals Albuquerque, NM
19. Jacob Kesner July 2016- June 2017	Antimicrobial Stewardship Clinical Pharmacist Lovelace Hospital Albuquerque, NM
20. Marco Custodio July 2017- June 2018	Surgical ICU Pharmacist Cabell Huntington Hospital Huntington, WV
21. Jenny Shroba July 2017- June 2018	Clinical Pharmacist Antimicrobial Stewardship Duke Raleigh Hospital Raleigh, NC
22. Maria Gabriela Cabanilla July 2018- June 2019	Clinical Pharmacist University Hospitals Albuquerque, NM

Director/Coordinator – Residency/Fellowship in Clinical Translational Pharmacy.

Developed and organized a 2-year training program, which focuses on utilizing new diagnostic methodologies to improve patient care. The program provides the resident with extensive clinical experience in antimicrobial stewardship, pharmacogenomics and new rapid diagnostic modalities. The residency is offered in collaboration with Tricore Laboratories who fund and provide the necessary diagnostic methods and clinical data for the fellow to learn how to utilize rapid diagnostic tools, educate health care providers about the new techniques and interpretation in order to positively impact direct patient care. Additionally, the resident gains research experience by designing, conducting and analyzing

studies. The residency is offered at the University of New Mexico – Health Sciences Center and Tricore Laboratories. The first resident began training in July 2014.

Monique Dodd, July 2014 - June 2016

Aya Haghmad, July 2016 – June 2017

Director – Infectious Diseases Pharmacotherapy Fellowship

Developed and organized a 1-year training program in infectious diseases. The program provides the fellow with extensive research experience in all areas of infectious diseases. Additionally, the fellow gains teaching experience by providing lectures, and supervising students on clerkship. The fellowship is offered at the University of New Mexico.

Thomas Dilworth, July 2012 – June 2013

Faculty Mentor

Karen Dominguez, Tenure-Track, July 2003 – June 30, 2006 (Faculty Tenured and Promoted)

Manjunath (Amit) Pai, Tenure-Track, July 2003 – June 30, 2007 (Faculty Tenured and Promoted)

Nancy Heideman, Clinical-Educator Track, June 2005 – 2008 (Faculty resigned 2008)

Mary Vilay, Tenure-Track, August 2009-June 2015 (Faculty Tenured and Promoted)

Jessica Conklin, Visiting Faculty, August 2013-June 2014

Student Mentor (For Student Working in my Laboratory)

B. Sc. Students: Christina Meadows, Robert Dietz, Jory Mazzola, Marie Samples, Jora Sliwinski-Heath, Mimi Precit, Julie Acosta.

Pharm.D. Students: Melinda Montoya, Jora Sliwinski-Heath, Brian Werth, Keenan Ryan, Monique Dodd, Jenny Shroba, Julie Acosta, Michael Bernauer, Jessica Lewis, Andrea Bustamante, Daniel Sanchez, Beverly Anderson, Haedi DeAngelis Brandy Hernandez.

Post-Doc Fellow: Omar Ibrahim PhD

Student Research Mentoring on Specific Research Project.

1. **Faculty Mentor: Brandy Hernandez Pharm.D. Candidate 2023.** Summer Research Fellowship \$4,000. Predicting susceptibility for methicillin-susceptible *Staphylococcus aureus*: a Clinical Conundrum.
2. **Faculty Mentor: Beverly Anderson Pharm.D. Candidate 2021.** Summer Research Fellowship \$4,000. Hospital preparedness for antiretroviral management of newborns with perinatal HIV exposure: a cross-sectional survey.
3. **Faculty Mentor: Haedi DeAngelis Pharm.D. Candidate 2022.**
4. **Faculty Mentor. Jenny Shroba Pharm.D. Candidate 2016.** College of Pharmacy 2014 Summer Research Fellowship \$4,000. Clinical Implications and Strain Characteristics of Recurrent Methicillin-Resistant *Staphylococcus aureus*.
5. **Faculty Mentor. Melinda Montoya Pharm.D. Candidate 2011.** College of Pharmacy 2009 Summer Research Fellowship \$4,000. Diflunisal effects on MRSA colonization and proliferation in an in vitro model of infective endocarditis.
6. **Project Advisor for Pharm.D. Student, Susan Kunkel - Pharm.D. Research Project.** Developing a Computer-Based Tool to Study the Pharmacotherapy of HIV-AIDS. March 2001 – May 2002.

7. **Project Advisor for Pharm.D. Student, Debra Krolik** - Pharm.D. Research Project. Adherence baseline assessment to highly active antiretroviral therapy (HAART) in the University of New Mexico Infectious Diseases Clinic. June 1999 – May 2001.
8. **Project Advisor for Pharm.D. Students, Nhat Vo and Brenda K. Murrah** - Pharm.D. Research Project. Association between the utilization of HAART and the development of anemia in HIV-infected persons living in New Mexico. January 1999 – May 2000.
9. **Project Advisor for Pharm.D. Student, Christine Kennedy** – Pharm.D. Research Project. Comparison of the bactericidal effect of GAR-936 against *Staphylococcus aureus* and *Enterococcus faecium* used singly and in combination with rifampin, doxycycline and gentamicin using time-kill studies. January 1999 – May 2000.
10. **Project Advisor for Pharm.D. student, Carmine Stumpo** - Infectious Diseases Research-Elective rotation. Student was introduced to in vitro research, methodology, practice and participation in the research project: The effect of growth phase and pH on the in vitro activity of a new glycopeptide, LY333328. April, 1997.
11. **Project Advisor for Infectious Diseases Fellow, Daniela Stokes, M.D.** - Research year-Introduction to laboratory work; MIC/MBC, killing curve experiments, in vitro model experiment, design of a research protocol, methodology and analysis of the data. Project: *Enterococcus faecalis* (EF) small (SCV) and large colony variants (LCV). February - December 1996.
12. **Project Advisor for Pharm.D. student, Scott Penzak** - Infectious Diseases Research-Elective rotation. Student was introduced to in vitro research, methodology, practice and participation in the research project: In vitro activity of investigational antibiotics alone and in combinations against two strains vancomycin-resistant *Enterococcus faecium* (VREF). February 1996.
13. **Study coordinator for Detroit Receiving Hospital** - Synercid® Clinical Trials. Skin and soft tissue, pharmacokinetic and compassionate use studies. Sponsored by Rhône-Poulenc Rorer and monitored by Concepts in Pharmaceutical Research and Icon Clinical Research. 1995-1997.
14. **Study coordinator for Detroit Medical Center** - Clarithromycin Clinical Study, Treatment of *Helicobacter pylori*. Sponsored by Abbott Laboratories and monitored by Pharmaceutical Product Development. 1995-1997.

Thesis Committee

Sarah Caroline Jordan MS student. The Role of the Accessory Gene Regulator Operon in *S. aureus* Biofilm Formation *in vitro/in vivo*. Member of her committee 2020-2022.

Salina Torres PhD student. Mutagenesis and Mitochondrial Alterations in Human of Mouse Cells Following In Vitro or In Utero Exposure to Single/Combined Nucleoside Reverse Transcriptase Inhibitors. Member of her committee 2006-2008.

Professional Activities

NIH Study Section - Grant Reviewer

Biodefense and Therapeutics SBIR NIH Study Section (2002-2003)

Journal Reviewer

1. American Journal of Health-System Pharmacy (1995-present)
2. Annals of Internal Medicine (1995-1998)
3. Antimicrobial Agents and Chemotherapy (1997-present)
4. Annals of Pharmacotherapy (1995–present)
5. Pharmacotherapy (1995-present)
6. Diagnostic Microbiology and Infectious Diseases (2013-present)
7. Journal of Pharmacy Technology (2013-present)
8. Microbial Drug Resistance (2014-present)
9. Journal of Managed Care and Specialty Pharmacy (2014-present)

Chapter Reviewer

1. Pharmacotherapy Self-Assessment Program, 5th ed., Infectious Diseases Book 6, Intravascular Access Device-related Infections Chapter. (2004-2005)
2. HIV AIDS Updates in Therapeutics: The Ambulatory Care Pharmacy Preparatory Course. 2012

Abstract Translator

Annals of Pharmacotherapy (1997–2000)

Professional Affiliations

- Canadian Association of Pharmacy Students and Interns (CAPSI) (1989–1993)
- Ordre des Pharmaciens du Québec (1993 – 1995)
- American Society of Health System Pharmacists (ASHP) (1994-present)
- American College of Clinical Pharmacy (ACCP) (1994-present)
- American Society for Microbiology (ASM) (1995-present)
- Society of Infectious Diseases Pharmacists (SIDP) (1995-present)
- Rho Chi Pharmaceutical Society (1995-present)
- Infectious Diseases Society of New Mexico (1997-present)
- American Association for the Advancement of Science (1997-2002)
- New Mexico Society of Health System Pharmacists (1998-present)
- Society of HealthCare Epidemiology of America (2009-2015)
- European Society of Clinical Microbiology and Infectious Diseases (1996-1998, 2013-present)

Committee Membership**University of New Mexico – College of Pharmacy**

2019-2020	Promotion and Tenure Committee – Borrego	Chair
2016-present	COP Research & Scholarship Committee	Chair-Member
2015-present	Promotion and Tenure Committee	Member
2017	PPAS CE Track Search Committee	Chair
2016-2018	COP Active Learning Task Force	Member
2015-2016	Faculty Development Committee	Vice-Chair
2014-2016	COP Residency/Fellowship Career Development	Member
2012-2014	Student Pharmacist Research Interest Group	Faculty Advisor
2014	Promotion and Tenure Committee	Vice-Chair
2013-2014	PPAS Department Chair Search Committee	Co-Chair
2013-2014	PCL Task Force	Member
2006-2013	Promotion and Tenure Committee	Chair
2013	Administrative Assistant Search Committee	Member
2012-2013	P&T Task Force	Member
2011	Grant Coordinator Search Committee	Member
2011-2011	Clinical Affairs Committee	Member
2010-2011	Dean Search Committee	Member
2010-2011	Curriculum Committee	Member
2009-2010	Grant Coordinator Search Committee	Member
2008-2012	Scholastic Achievement and Progression Committee	Member
2007-2009	Organization, Planning and Evaluation SubCommittee	Member
2007-2009	Search Committee 2 CE/1 Tenure-track faculty position	Member
2005-2006	Fiesta committee	Member
2003-2006	Promotion and Tenure Committee	Member
2003-2006	Space Allocation Committee	Member
2000-2003	Student Services Committee	Member
1998-2000	Emergency Student Loan Committee	Member

University of New Mexico – Health Sciences Center

2019-present	HSC Conflict of Interest Committee	Vice-Chair
2016-2019	HSC Conflict of Interest Committee	Chair
2003-present	UNM-HSC Residency Committee	Co-Chair
1998-present	Pharmacy & Therapeutics Antibiotics Subcommittee	Member
2012-2016	HSC Conflict of Interest Committee	Member
2004-2010	Credentialing Task Force PPAS reimbursement	Member
1999-2003	Disaster Medicine Assistance Team	Pharmacist

Society of Infectious Diseases Pharmacists

2014-2015	Research Award Committee	Chair
2007-2008	Award Committee	Member
2006-2007	Award Committee	Chair
2005-2006	Award Committee	Member
2002-2003	Membership Committee	Chair
2000-2002	Membership Committee	Member
1999-2000	Award Committee	Member

American College of Clinical Pharmacy –

1998-present	Infectious Diseases PRN committee	Member
--------------	-----------------------------------	--------

2002-2003	Infectious Diseases PRN committee	Secretary/Treasurer
-----------	-----------------------------------	---------------------

European Society of Clinical Microbiology and Infectious Diseases

2013-present	ESCMID Study Group for Staphylococci and Staphylococcal Diseases	Selected member
--------------	--	-----------------

American Society of Health-System Pharmacist

2016-2017	ASHP Foundation New Investigator Grant	Reviewer
2015-2016	ASHP Foundation New Investigator Grant	Reviewer
2014-2015	ASHP Foundation New Investigator Grant	Reviewer
2013-2014	ASHP Foundation New Investigator Grant	Reviewer
2003-2008	ASHP Student Forum	Faculty Advisor

Invited Consultant

1. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. April 2010. Dallas, TX.
2. Astellas Pharmaceuticals. Speakers bureau meeting. Speakers were invited to review and advise Astellas on prospective talk to be given regarding Telavancin. October 2009. Chicago, IL.
3. Astellas Pharmaceuticals. Regional Advisory Board meeting. Consultants were invited to advise Astellas on issues related to the marketing and pharmacologic properties of Telavancin. August 2009. San Francisco, CA.
4. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. October 2009. Boston, MA.
5. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. June 2009. Dallas, TX.
6. Astellas Pharmaceuticals. Regional Advisory Board meeting. Consultants were invited to advise Astellas on issues related to the marketing and pharmacologic properties of Telavancin. March 2009. San Diego, CA.
7. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. September 26-27, 2008. Chicago, IL.
8. EPCP Emerging Pathogens Consult Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. January 31-February 2, 2008. San Diego, CA.
9. Ortho McNeil. Antimicrobial Regional Advisory Board Meeting. Consultants were invited to advise Ortho McNeil on issues related to the marketing and pharmacologic properties of two new injectable antibiotics currently in development. November 2007, Dallas, TX.
10. Ortho McNeil. Antimicrobial Regional Advisory Board Meeting. Consultants were invited to advise Ortho McNeil on issues related to the marketing and pharmacologic properties of two new injectable antibiotics currently in development. October 2007, New Orleans, LA.
11. Ortho McNeil. Antimicrobial Regional Advisory Board Meeting. Consultants were invited to advise Ortho McNeil on issues related to the marketing and pharmacologic properties of two new injectable antibiotics currently in development. September 2007, Chicago, IL.
12. EPCP Emerging Pathogens Consult Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. July 14-16, 2006. San Francisco, CA.

13. Aventis. ID/Pharm.D. National Visiting Professor Specialty Academy. Consultants were invited to advise Aventis Pharmaceuticals on issues related to the marketing and pharmacologic properties of Telithromycin. June 23-24, 2006. Chicago, IL.
14. Cubist Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. April 21-22, 2006. Atlanta, GA.
15. Aventis. ID/Pharm.D. National Visiting Professor Specialty Academy. Consultants were invited to advise Aventis Pharmaceuticals on issues related to the marketing and pharmacologic properties of Telithromycin. September 9-10, 2005. Chicago, IL.
16. EPCP Emerging Pathogens Consult Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. February 25-27, 2005. New York, NY.
17. Tigecycline Advisory Board meeting (Wyeth-Ayerst). Consultants were invited to advise Wyeth Pharmaceuticals on issues related to the marketing and pharmacologic properties of Tigecycline. February 24-25, 2005. New York, NY.
18. Aventis. ID/Pharm.D. National Visiting Professor Specialty Academy. Consultants were invited to advise Aventis Pharmaceuticals on issues related to the marketing and pharmacologic properties of Telithromycin. August 20-21, 2004. Chicago, IL.
19. Cubist Pharmaceuticals Inc. Chair - Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. February 28, 2004. Bernalillo, NM.
20. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. February 20-22, 2004. Copper Mountain, CO.
21. EPCP Emerging Pathogens Consult Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. February 6-8, 2004. Marco Island, FL.
22. GlaxoSmithKline. HIV Clinical Pharmacy Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral therapy. January 16-18, 2004. Phoenix, AZ.
23. Cubist Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. December 7, 2003. New Orleans, LA.
24. Cubist Pharmaceuticals Inc. Speakers bureau meeting. Speakers were invited to review and advise Cubist Pharmaceuticals on prospective talk to be given regarding Daptomycin. July 25-26, 2003. West Palm Beach, FL.
25. King Pharmaceuticals, Inc. Advisory Board meeting. Consultants were invited to advise King Pharmaceuticals on issues related to the marketing and pharmacologic properties of Synercid. June 4-5, 2003. Las Vegas, NV.
26. Pfizer Pharmaceuticals, Inc. Consultant meeting regarding the role of Azithromycin in the treatment of upper respiratory tract infections. May 3, 2003. Orlando, FL.
27. Merck Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Merck on issues related to the marketing and pharmacologic properties of Ertapenem. May 1 & 2, 2003. Chicago, IL.
28. Pharmacia and Upjohn Advisory Board meeting. Consultants were invited to advise Pharmacia and Upjohn on issues related to the marketing and pharmacologic properties of Zyvox. March 12-16, 2003. Las Vegas, NV.
29. EPCP Emerging Pathogens Consult Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. February 7-9, 2003. Phoenix, AZ.

30. Cubist Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. December 6, 2002. Atlanta, GA.
31. Merck Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Merck on issues related to the marketing and pharmacologic properties of Ertapenem. November 15, 2002. Washington, DC.
32. Aventis. ID/Pharm.D. National Visiting Professor Specialty Academy. Consultants were invited to advise Aventis Pharmaceuticals on issues related to the marketing and pharmacologic properties of Telithromycin. September 12-14, 2002. Wilmington, DE.
33. GlaxoSmithKline. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral resistance. August 15-16, 2002. Dallas, TX.
34. EPIC Clinical Pharmacy Speaker Education Training Program (Wyeth-Ayerst). Consultant and speaker services training required to facilitate the education of health care professionals on emerging pathogens and interventions for clinicians. August 9-11, 2002. San Diego, CA.
35. Merck & CO., Inc. Infectious Disease Thought Leader Market Research. Consultants were invited to give feedback to Merck on issues related to the marketing and pharmacologic properties of Invanz. March 8-9, 2002. Phoenix, AZ.
36. Pharmacia and Upjohn Advisory Board meeting. Consultants were invited to advise Pharmacia and Upjohn on issues related to the marketing and pharmacologic properties of Zyvox. February 20-24, 2002. Las Vegas, NV.
37. GlaxoSmithKline. HIV Clinical Pharmacy Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral therapy. February 9-10, 2002. Tuscon, AZ.
38. Cubist Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. December 1, 2001. New Orleans, LA.
39. GlaxoSmithKline. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral therapy. August 17, 2001. Carlsbad, CA.
40. GlaxoSmithKline. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral resistance. May 19, 2001. Dallas, TX.
41. GlaxoSmithKline. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise GSK on issues related to antiretroviral resistance. May 9, 2001. Phoenix, AZ.
42. Cubist Pharmaceuticals Inc. Advisory Board meeting. Consultants were invited to advise Cubist Pharmaceuticals on issues related to the marketing and pharmacologic properties of Daptomycin. May 5, 2001. Orlando, FL.
43. Pharmacia and Upjohn Advisory Board meeting. Consultants were invited to advise Pharmacia and Upjohn on issues related to the marketing and pharmacologic properties of Zyvox. April 25-27, 2001. Key West, FL.
44. EPIC Clinical Pharmacy Speaker Education Training Program (Wyeth-Ayerst). Consultant and speaker services required facilitating the education of health care professionals on emerging pathogens and interventions for clinicians. February 23-25, 2001. Boca Raton, FL.
45. Glaxo Wellcome Inc. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise Glaxo Wellcome on issues related to the treatment of HIV, with emphasis on long term complications of HIV drug therapy. September 29, 2000. Albuquerque, NM.
46. Glaxo Wellcome Inc. HIV Regional Scientific Consultant Meeting. Consultants were invited to advise Glaxo Wellcome on issues related to the treatment of HIV, with emphasis on long term complications of HIV drug therapy. June 16-17, 2000. Rancho Mirage, CA.
47. Pfizer Pharmaceuticals, Inc. "Zithromax I.V. Pharmacist Speaker Training Program". Consultant and speaker services required facilitating the education of health care professionals on I.V. azithromycin. Conducted by JL Shapiro and Assoc. October 23, 1999. Kansas City, MO.

48. Bayer Corporation. "Infectious Diseases in the 1990s: Challenges and Solutions". Meeting set to discuss controversial ID issues with US infectious disease specialists. March 20-22, 1998. San Francisco, CA.
49. Rhône Poulenc Rorer. "Clinical Challenges, Pharmacy Solutions". Consultant for RPR as it pertains to their new antimicrobial, Synercid®. February 26-28, 1998. Phoenix, AZ.
50. Pfizer Pharmaceuticals, Inc. Consultant services required for the scientific promotion of the new released quinolone Trovafloxacin conducted by ASHP ADVANTAGE and sponsored by Pfizer. November 9, 1997. Phoenix, AZ.

Clinical Services

Infectious Diseases Consult Service. University of New Mexico – Health Sciences Center. Pharmacotherapy specialist for patients and healthcare professionals. (1997-present, 10-20 hours/week X 2-3 months/year). Services provided to the inpatient population of University Hospital include evaluation and monitoring of drug therapy, participation in drug selection and patient education.

Pregnancy Clinic for Women living with HIV. University of New Mexico – Health Sciences Center currently part of Truman Health Services. (4 hours/month). Responsible for establishing a care coordination clinic for all women who are pregnant and living with HIV at Truman and across the State of New Mexico. Monthly appointment while pregnant, medication adjustment based on contraindications and trimester, education surrounding pregnancy, delivery and newborn HIV exposed care. Coordination between OB/Gyn, Family medicine, and HIV care provider to ensure appropriate delivery plan based on HIV determinants, medication availability, protocols, etc... Services provided also include evaluation and monitoring of drug therapy, participation in drug selection and patient education. Time is also spent providing care for the HIV pediatric population, HIV pregnant women and Young Adult infected

Pediatric HIV Clinic. University of New Mexico – Health Sciences Center Pediatrics. Pharmacotherapy specialist for HIV infected patients, children, and newborns exposed to HIV. (4 hours/week). Responsible for establishing an adherence program and a specialized pharmaceutical care clinic. Services provided also include evaluation and monitoring of drug therapy, participation in drug selection and patient education. Developing protocols and SOP. The target population is pediatric patients living with HIV and children exposed to HIV.

Young Adult HIV Clinic. University of New Mexico – Health Sciences Center currently part of Truman Health Services. Pharmacotherapy specialist for HIV infected patients and healthcare professionals. (5 hours/week). Responsible for establishing an adherence program and a specialized pharmaceutical care clinic. Services provided also include evaluation and monitoring of drug therapy, participation in drug selection and patient education. Developing protocols and SOP. Target population are young adult aged 15-26 years of age living with HIV.

PrEP Clinic. University of New Mexico - Health Sciences Center currently part of Truman Health Services. Responsible for designing and implementing a pharmacist run PrEP clinic that serves the Greater Albuquerque area. Clinic was started in July 2015 and meets ½ day per week. Services include evaluation for PrEP initiation, monitoring of drug therapy, patient follow-up and education. PEP is also now provided as part of the this clinic

Antimicrobial Stewardship ECHO (Extension for Community Healthcare Outcomes) Clinic. ECHO is a collaborative model of medical education and care management that empowers clinicians everywhere to provide better care to more people, right where they live. Created, lead and serve as one of the medical directors of the Stewardship ECHO 2-4 times per month for a 1-hour session in addition to planning meetings quarterly for 2-3 hours each. Hiatus in May 2020 due to overwhelming need for Covid ECHO clinic.

Covid ECHO (Extension for Community Healthcare Outcomes) Clinic. ECHO is a collaborative model of medical education and care management that empowers clinicians everywhere to provide better care to more people, right where they live. Created, lead and serve as one of the medical directors of the Covid ECHO 4 times per month for a 1-hour session. April to September 2020.

HIV ECHO (Extension for Community Healthcare Outcomes) Clinic. ECHO is a collaborative model of medical education and care management that empowers clinicians everywhere to provide better care to more people, right where they live. Provide education and consultation for the HIV Telemedicine clinic 2 hours/month.

OPAT (Outpatient Parenteral Antimicrobial Therapy) Specialty Clinic. University of New Mexico – Health Sciences Center. Pharmacotherapy specialist in a healthcare multidisciplinary team.

2007- 2010: Pharmacist Clinician serving as Mid-Level Provider 5 hours/week.
(1997-2003, 4 hours/week) Referral center for osteomyelitis, diabetic foot infections and patients receiving home IV antibiotics. Services provided include evaluating and monitoring drug therapy, participation in drug selection and patient education.

Other Services

Immunization Clinics - Provide supervision for students and administer flu vaccination in clinic held throughout the UNM Health Sciences Campus. Time commitment has varied from few hours per year to 5 days/year. 2005-present.

National AETC Pharmacy Faculty Development Workshop. AIDS Education and Training Center Pharmacist for the State of New Mexico. August 10th, 11th, 2001, UCSF, San Francisco, CA.

New Mexico Residents' and Fellows' Journal Club Meetings. Responsible for developing, and coordinating the Journal Club dinner meetings 5-6 X/year from 2001-2003.

Community Service

1. Tennis Club of Albuquerque, Swim Team Organizer. May to August (Summer 2014 until present). Organize swim meets, communications between swim team members and coaches, and all social events.
2. Instructor, Adaptive Ski Program, Winter 1999-2000. Santa Fe, NM.
3. Volunteer Judge for the 47th New Mexico Science and Engineering Fair, April 1999. Socorro, NM.
4. Volunteer pharmacotherapy specialist consultant at the 1999 AIDS retreat in Ruidoso, NM. March 1999.
5. Red Cross/United Blood Services. Blood donor since 1987.